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Summary 
The National Cervical Screening Program (NCSP) aims to reduce cervical cancer cases, as 
well as illness and death from cervical cancer in Australia, through an organised approach to 
cervical screening aimed at detecting and treating high-grade abnormalities before possible 
progression to cervical cancer. The target group is women aged 20–69. 
This report is the latest in the Cervical screening in Australia series, which is published 
annually to provide regular monitoring of NCSP participation and performance.  
The following statistics are the latest data available for women aged 20–69. 
Cervical cancer cases and deaths are low by international standards  
There were 682 new cases diagnosed in 2011 and 143 women died from cervical cancer in 
2012. This is equivalent to between 9 and 10 new cases of cervical cancer diagnosed per 
100,000 women in 2011 and 2 deaths from cervical cancer per 100,000 women in 2012. These 
age-standardised rates are very similar to those for 2010 and 2011, respectively. 
Both incidence and mortality halved between the introduction of the NCSP in 1991 and the 
year 2002, and have since remained at around 9 new cases and 2 deaths per 100,000 women. 
Incidence of cervical cancer in Aboriginal and Torres Strait Islander women was more than 
twice that of non-Indigenous women, and mortality was 4 times the non-Indigenous rate. 
Around 6 in 10 women participate in the National Cervical Screening Program 
In 2012–2013, more than 3.8 million women participated in the NCSP. This was 58% of 
women aged 20–69. This age-standardised rate is similar to 2010–2011 and 2011–2012, for 
which the participation rate was 57% and 58%, respectively. 
Participation differed only a little across remoteness areas, ranging between 58% and 60% in 
all areas except for Very remote areas where it was 55% (age-standardised rates).  
There was a clear trend of increasing participation with increasing socioeconomic status of 
residence, from 52% in areas of lowest socioeconomic status to 64% in areas of highest 
socioeconomic status (age-standardised rates).  
National participation rates for Aboriginal and Torres Strait Islander women are not 
available due to Indigenous status information not being collected on pathology forms in all 
jurisdictions, although there is evidence that this population group is under-screened. 
Relatively few women rescreen early, and a third respond to a reminder letter 
Only 13% of women with a negative Pap test in 2012 rescreened earlier than recommended. 
Of the women sent a 27-month reminder letter by a cervical screening register in 2012,  
33% rescreened within 3 months. These figures are both very similar to those for 2011. 
High-grade abnormality detection the same, despite decreases in ages <25 
In 2013, for every 1,000 women screened, between 8 and 9 women had a high-grade 
abnormality detected by histology, providing an opportunity for treatment before possible 
progression to cancer. This age-standardised rate is similar to 2012, for which the rate was 8. 
While the detection of high-grade abnormalities was most common among women aged  
25-29, there were historically low rates of detection for women aged under 20 and 20-24.
   vii 
Report card 
 Latest data Is this a good finding? Previous data How compares Recent trend 
Participation in 2012–2013 58.2%  Yes (higher is better) 57.7%  Similar Steady at 57–58%  
Early rescreening 12.6%  Yes (lower is better) 13.0%  Similar Falling from 15 to 13%  
Rescreening after reminder letter 32.7%  Yes (higher is better) 31.8%  Similar Steady at 32–33%  
Pap tests not of satisfactory quality 2.2%  Yes (lower is better) 2.2%  Similar Steady at 2%  
Pap tests negative for abnormalities 91.9%  Yes  92.1%  Similar Steady at 92%  
Pap tests with no endocervical component 22.5% Χ No (<20% is better) 21.9%  Similar Rising from 20 to 23%  
High-grade abnormality detection in 2013 8.5  Yes  8.4  Similar Steady at 8.4–8.5  
PPV of high-grade squamous cytology 68.3%  Yes (higher is better) 68.2%  Similar Steady at 68–70%  
PPV of high-grade endocervical cytology 73.0%  Yes (higher is better) 71.4%  Similar Steady at 71–74%  
Incidence in 2011 9.5  Yes (lower is better) 9.6  Similar Steady at 9.0–9.6  
Mortality in 2012 1.8  Yes (lower is better) 2.0  Similar Steady at 1.8–2.0  
Report card uses age-standardised rates where available to aid in comparison of trends.  All data shown are for women aged 20–69. 
Green light: positive trend—all is well. Amber light: trend slipping in an unfavourable direction—keep an eye on this. Red light: unfavourable trend—may be cause for concern. 
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Navigating changes in this report 
Regular users of this annual monitoring report will notice that Cervical screening in Australia 2012–2013 looks a little different to the previous 
report Cervical screening in Australia 2011–2012. The same data have been provided, along with much of the same information, but the structure 
and format have changed. Therefore this ‘map’ has been provided to aid regular users in the navigation of this report to ensure they are still 
able to find the data and information they require. 
Where are all the data tables? 
All the data tables that used to be interspersed amongst the text  
of each performance indicator chapter now appear together in  
Appendix A. These tables appear in the same order, and are  
numbered according to the performance indicator (for example,  
participation data tables, being indicator 1, are numbered from  
A1.1 to A1.7, and rescreening tables are numbered from A2.1 to  
A2.2), so that regular users can still access the detailed data as  
usual.  
Why are fewer data being reported? 
Regular users will also notice that the sections that report on data are shorter and described differently. Whereas there used to be a chapter for 
each performance indicator, with every result for every disaggregation reported, only selected results appear in this report, with a focus on the 
most important findings—the ‘story’ of what occurred in cervical screening in 2012–2013. Further, data from different performance indicators 
have been incorporated into a single chapter so that data can be discussed in context, rather than isolation. This means that participation and 
rescreening data are reported together in a chapter called Screening behaviour, cytology and cytology-histology correlation data are reported 
together in a chapter called Characteristics of the screening test and selected histology data are reported in a chapter called Detection of high-grade 
abnormalities. The overall aim of these changes is to have key information easy to find whilst removing any repetition or redundancy in the text 
that might mask key findings. 
Note that the fact that some data are not reported does not imply these are not important to monitor; all data are analysed and monitored. 
Where has the information from the introduction gone? 
In response to feedback, the introductory section is now much shorter, but key information has been retained, and, rather than appearing in 
one solid block at the beginning of the report, is now dispersed within the relevant sections of the text, glossary and appendices. 
Indicator … Appendix A 
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1 Introduction 
1.1 Cervical cancer 
Cancer is a group of several hundred diseases in which abnormal cells are not destroyed 
naturally by the body but instead multiply and spread out of control. Cancers are 
distinguished from each other by the specific type of cell involved and the place in the body 
in which the disease began.  
Cervical cancer affects the cells of the  
uterine cervix, which is the lower part  
(or ‘neck’) of the uterus where it joins the 
inner end of the vagina. Cervical cancer 
develops when abnormal cells in the lining  
of the cervix begin to multiply out of control 
and form precancerous lesions. If undetected, 
these lesions can develop into tumours and 
spread into the surrounding tissue. 
Worldwide, cervical cancer is the fourth most 
common cancer affecting women and the 
seventh most common cancer overall; 
however, the burden of cervical cancer is not 
equal globally—around 85% of the global 
burden occurs in the less developed regions, 
where cervical cancer accounts for almost 
12% of all female cancers (IARC 2014). In 
contrast, in Australia cervical cancer accounts 
for less than 2% of all female cancers, with a 
relatively low incidence of 7 new cases  
per 100,000 women (AIHW 2014a). 
1.2 The primary cause of cervical cancer is HPV 
It has been recognised for some time that cervical cancer is a rare outcome of persistent 
infection with one or more oncogenic (cancer-causing) types of human papillomavirus 
(HPV) (Bosch et al. 2002; Walboomers et al. 1999). These oncogenic types of HPV are known 
as ‘high-risk’ HPV, and infection with one or more of these is the underlying cause of almost 
all cases of cervical cancer. Currently 15 high-risk types of HPV are recognised. HPV types 
16, 18, and 45 are most predominantly associated with cervical cancer, with HPV types 16 
and 18 detected in 70–80% of cases of cervical cancer in Australia (Brotherton 2008).  
However, infection with one or more of the 40 genital HPV types is extremely common, with 
infection rates of this sexually transmitted infection peaking in women in young adulthood 
(the period following sexual debut). Most HPV infection is asymptomatic and cleared by the 
immune system within a year; however, in up to 10% of women the infection can persist, and 
in a very small number of women, persistent infection with high-risk HPV may eventually 
lead to cervical cancer. 
 
Figure 1.1: Anatomy of the cervix and nearby 
organs 
© National Cancer Institute 2014. 
Source: <http://visualsonline.cancer.gov>. 
Reproduced with permission of the copyright owner. 
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The 4 major steps in cervical cancer development are infection with HPV (from sexual 
activity), viral persistence (most HPV infections clear with no treatment), progression to 
precancerous abnormalities (many of which will also regress with no treatment) and invasive 
cervical cancer (Schiffman et al. 2007) (Figure 1.2). Note that this is not unidirectional, and 
that most HPV-infected cells return to normal and a large proportion of precancerous 
abnormalities do not progress to cervical cancer, even in the absence of treatment. 
 
 
 
 
 
 
 
 
Source: Reproduced with permission from M Schiffman, National Cancer Institute (Schiffman 2003). 
Figure 1.2: Role of human papillomavirus infection in the development of cervical cancer 
Infection of cervical cells with high-risk HPV interferes with the normal functioning of these 
cells, leading to abnormalities in the cells that we recognise as precancerous changes. 
However, while the cell changes caused by persistent infection with HPV are necessary for 
the development of precancerous changes to the cervix, there are a range of other factors that 
will influence whether precancerous changes will progress to cervical cancer, including 
smoking; multiparity (specifically more than 5 full-term pregnancies); a young age at first 
full-term pregnancy; oral contraceptive use; and immunosuppression (Cancer Council 
Australia 2014). 
1.3 Cervical cancer is a largely preventable disease 
The role HPV plays in the development of cervical cancer allows for the implementation of 
both primary and secondary strategies for the prevention of cervical cancer, in those 
countries that have available resources to make cervical cancer prevention a priority. 
In Australia, primary prevention of cervical cancer is through vaccination against HPV 
through the National HPV Vaccination Program to prevent women being infected with high-
risk HPV types 16 and 18. Secondary prevention of cervical cancer is through cervical 
screening through the National Cervical Screening Program (NCSP) to detect and treat 
abnormalities while they are in the precancerous stage, before any possible progression to 
cervical cancer. This is possible because cervical cancer is one of the few cancers that has a 
precancerous stage that lasts for many years prior to the development of invasive disease, 
which provides an opportunity for detection and treatment (WHO 2014). 
Detection of precancerous abnormalities through cervical screening uses cytology from the 
Papanicolaou smear, or ‘Pap test’, as the screening tool. During a Pap test, cells are collected 
from the transformation zone of the cervix—the area of the cervix where the squamous cells 
from the outer opening of the cervix and glandular cells from the endocervical canal meet. 
This is the site where most cervical abnormalities and cancers are detected. 
Mild cytologic and/or 
histologic abnormalities 
Infection 
Clearance 
Progression 
Regression 
Invasion 
Normal cervix HPV-infected cervix Precancer Cancer 
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While cervical cytology, the examination of the cells collected from the cervix, is a very 
useful tool, it is not diagnostic. As a screening tool, the aim of cervical cytology is to identify 
those individuals who may have a cervical abnormality (as indicated by the presence of 
abnormal cells in the specimen collected) and therefore require further diagnostic testing. 
Since the Pap test collects an arbitrary sample of cells from the surface of the cervix at an 
arbitrary point in time, and requires a level of judgment in the interpretation of sampled 
cells, cervical cytology cannot accurately reveal all abnormalities that may exist in the 
cervical tissue in situ.  
The strength of cervical screening comes from repeating the cervical cytology test at agreed 
rescreening intervals, which allows the accurate detection of precancerous abnormalities 
over the long preinvasive stage of squamous cervical cancers. Recognition of cervical 
screening as a program of rescreening at regular intervals rather than as a single 
opportunistic test was important in the establishment of the NCSP (Dickinson 2002). 
Detecting precancerous changes to cells allows for intervention before cervical cancer 
develops, so high participation in cervical screening reduces both an individual’s risk and 
the incidence and burden of cervical cancer in Australia overall. 
It is also important to recognise that some cervical cancers do not have a precancerous stage, 
and therefore are simply unable to be detected by cervical screening. These tend to be rare 
but aggressive cancers such as neuroendocrine cancer of the cervix, the two most aggressive 
types being small cell neuroendocrine carcinoma and large cell neuroendocrine carcinoma, 
neither of which appear to possess a preinvasive stage (Necervix.com 2014). 
Box 2.1 Key messages 
Cervical cancer is a rare outcome of persistent infection with high-risk HPV  
Oncogenic types of HPV are known as ‘high-risk’ HPV, and infection with one or more of 
these is the underlying cause of almost all cases of cervical cancer. 
Infection with HPV is very common, and most infections will resolve spontaneously. It is 
only in a very small number of women that infection with a high-risk HPV persists, which 
may lead to precancerous abnormalities and—if not detected by cervical screening and 
treated—may progress to cervical cancer in around 10 to 20 years. 
Cervical cancer is a largely preventable disease   
In Australia, primary prevention of cervical cancer is through vaccination against HPV, 
through the National HPV Vaccination Program, to prevent women being infected with 
high-risk HPV types 16 and 18. Secondary prevention of cervical cancer is through cervical 
screening, through the NCSP, to detect and treat abnormalities while they are in the 
precancerous stage, before any possible progression to cervical cancer. 
Cervical screening is possible because cervical cancer is one of the few cancers that has a 
precancerous stage that lasts for many years prior to the development of invasive disease, 
which provides an opportunity for detection and treatment. Note, however, that some rare 
(and often aggressive) cervical cancers do not have a precancerous stage, and therefore are 
simply unable to be detected by cervical screening. 
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2 The current state of cervical screening 
in Australia: on the cusp of change 
In early 2015 it seems likely that cervical screening in Australia is going to undergo a major 
change in the next few years. 
Ever since cervical screening began, women have been screened for cervical abnormalities 
and cancer using the Pap test—whether on an ad hoc basis prior to the introduction of the 
NCSP, or every 2 years as has been recommended by the NCSP since its inception in 1991. 
However, there have been many developments over the past 2 decades that mean that the 
environment in which the NCSP operates is very different from what existed in 1991. The 
main driver has been a greater understanding of the natural history of cervical cancer and 
the role HPV infection plays in this disease, as this has led to an examination of the optimal 
screening age range and interval internationally; the development of methods to test for the 
presence of HPV, and subsequently, a vaccine against HPV and the introduction of the 
National HPV Vaccination Program in 2007. By protecting vaccinated women from infection 
with the high-risk HPV types 16 and 18, the vaccination program will reduce the number of 
cervical abnormalities and eventually the incidence of cervical cancer, which will affect both 
the effectiveness and cost-effectiveness of the current NCSP. Thus it was recognised that the 
NCSP would need to change to adapt to this different environment and while continuing to 
operate according to current evidence and best practice. 
In light of this, in 2011, the former Australian Population Health Development Principal 
Committee of the Australian Health Ministers Advisory Council (AHMAC) endorsed a plan 
to renew the NCSP (‘the Renewal’), which commenced in 2011, undertaken by the Standing 
Committee on Screening and supported by the Department of Health. The aim of the 
Renewal is to ensure that all Australian women, HPV-vaccinated and unvaccinated, have 
access to a cervical screening program that is safe, acceptable, effective, efficient and based 
on current evidence (MSAC 2014). 
On 28 April 2014 the Medical Services Advisory Committee (MSAC) announced its 
recommendations for a renewed NCSP. These recommendations include 5-yearly cervical 
screening of HPV-vaccinated and unvaccinated women 25 to 69  years of age, using a 
primary HPV test with partial HPV genotyping and reflex liquid-based cytology (LBC) 
triage, followed by exit testing of women 70 to 74 years of age (MSAC 2014). This is a major 
change from the current program, which recommends 2-yearly cervical screening using Pap 
tests for HPV-vaccinated and unvaccinated women from 18 to 20 years (or 1 or 2 years after 
first having sexual intercourse, whichever is later) to 69 years. 
Importantly, if these recommendations are endorsed and the NCSP changed in this way, it 
would mean that Australia would lead the way in the prevention of cervical cancer, being 
the first to introduce a national school-based HPV vaccination program and one of the first to 
have a national cervical screening program that uses a primary HPV test as its screening test.   
So while this report monitors the NCSP as it currently exists and according to current policy 
and recommendations, it does so in the context of a shifting environment, and with the 
knowledge that these data may also serve the dual purpose of setting benchmarks prior to a 
major change in cervical screening in Australia. 
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3 Monitoring cervical screening in 
Australia using NCSP data 
3.1 Screening behaviour 
Cervical screening in Australia is not provided by a dedicated service, but is part of primary 
health care. Therefore all women who choose to have a cervical screening test (currently the 
Pap test) through any health-care provider are considered to be part of the NCSP. For 
women participating in cervical screening, being part of the NCSP means that there are 
standards for laboratories that interpret Pap test results, evidence-driven guidelines to aid in 
the management of women after they receive Pap test results, and dedicated cervical 
screening registers that act as a ‘safety net’ for participating women as well as encouraging 
regular Pap tests. 
One indicator of the performance of the NCSP is the proportion of women in the population 
who participate in cervical screening—measured as the percentage of women in the 
population aged 20–69 who had at least 1 Pap test in a 2-year period (to align with the 2-year 
recommended screening interval). High participation in screening is required for the NCSP 
to achieve its major objective of reducing cervical cancer incidence, morbidity and mortality, 
as more cervical abnormalities can be detected and treated that could otherwise develop into 
cervical cancer. 
Box 3.1 Crude versus age-standardised rates 
This report presents crude and age-standardised rates. Crude is the ‘true’ proportion or 
rate, and is appropriate when a single year or reporting period is reported (for example, 
crude participation in 2012–2013 was 57.7%). However, comparisons over time or across 
states/territories or population subgroups require that crude rates are age-standardised to 
remove the underlying differences in age-structure over time or between groups. These 
allow analysis of trends and differentials, and are therefore preferentially reported in these 
situations (for example, the age-standardised participation rate in 2012–2013 was 58.2%). 
In 2012–2013, the latest 2-year period, 3,815,705 women aged 20–69 participated, which is 
57.7% of the population who should have had a Pap test over this time.  
Participation for 2012–2013 has been age-standardised to 58.2%, which is the rate used when 
comparing participation (and other measures of performance) over time or across population 
subgroups such as state and territory, remoteness areas, and socioeconomic status groups. 
Using the age-standardised rate allows us to see that participation in 2012–2013 is similar to 
the participation of previous 2-year periods, as indicated by the dark blue line in Figure 3.1. 
Figure 3.1 also shows that the number of women screened in each 2-year period, indicated by 
the light blue columns, increases steadily from year to year.  
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Note: Rates from before 2004–2005 should not be directly compared with those after this reporting period (see Table A1.1).  
Source: AIHW analysis of state and territory cervical screening register data. 
Figure 3.1: Participation of women aged 20–69 in cervical screening, 1996–1997 to 2012–2013 
Although not aligning with the recommended screening interval, participation in the NCSP 
is also measured over a 3-year and 5-year period. Three-year participation, which was 70.3% 
in 2011–2013, is particularly relevant, as this may provide a more accurate indication of the 
proportion of women who participate regularly in cervical screening than 2-year data. 
This is because women are only reminded to screen after they have missed their next Pap 
test, not before their next Pap test is due. Women who respond to being reminded to screen 
after more than 2 years have past by having a Pap test will then be counted in the 3-year 
participation data, but not the 2-year participation data. 
In this way, this reminder to screen, in the form of a letter sent by a cervical screening 
register 27 months after a previous negative Pap test, can act as a ‘prompt’ for women to 
have their next Pap test. This is supported by rescreening data, which show that 32.7% of 
women who were sent this reminder letter in 2012 screened within 3 months.  
From these analyses it is clear that regular screeners comprise 58–70% of the population, but 
this alone does not tell us who are participating well and thus reaping the benefits of cervical 
screening, and who are participating less frequently, or not at all. For this, we need to look at 
different characteristics of women who participate in cervical screening. 
Screening behaviour across ages 
The first thing that is apparent is that age is a major determinant of screening behaviour. The 
effect of age on participation in cervical screening is very similar for 2-year and 3-year 
participation. The peak level of participation was 64.5% for 2-year participation and 77.5% 
for 3-year participation, in both cases seen in women aged 45–49 (Figure 3.2).  
The age structure changes when participation is measured over 5 years. The age group with 
the highest participation shifts to women aged 30–34 and 35–39 for 5-year participation, and 
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the age group with the lowest participation changes from women aged 20–24 for 2-year and 
3-year participation to  women aged 65–69 for 5-year participation (Figure 3.2). 
 
Source: AIHW analysis of state and territory cervical screening register data. Data for this figure are available in tables A1.2 and A1.6. 
Figure 3.2: Participation of women aged 20–69, by age, over 2 years (2012–2013), 3 years (2011–2013), 
and 5 years (2009–2013) 
The relatively low (and falling) level of screening in women aged 20–24 is not considered to 
be a cause for concern, as evidence shows screening women aged 20–24 years does not 
prevent any cervical cancers in women under the age of 25 years (Landy et al. 2014). 
Australia is one of the few countries that still screens women younger than 25, and, as 
outlined in the introductory material, MSAC recommendations include a starting age of 25 in 
Australia to be adopted as part of a renewed NCSP.  
While participation data show that many women screen less often than recommended, there 
are some women who screen more often than required—12.6% of women with no history of 
disease screen fall into this category. A low proportion of women rescreening early is 
desirable, since modelling has shown that a decrease in early rescreening reduces the cost of 
a screening program without changing its effectiveness (Creighton et al. 2010). 
This relatively low number continues a falling trend. While it represents a substantial 
decrease from 46.7 in 1997, there have been 2 changes to the definition of early rescreening 
that affect direct comparisons, as it is not possible to know how much of the decrease is due 
to the change in definition and how much is due to a true change in screening behaviour. 
Nonetheless, the overall trend shows a change in screening behaviour over time towards 
compliance with the recommended screening interval. More recently (and directly 
comparable since the same definition of early rescreening applied), the proportion of women 
rescreening early decreased from 15.1% in 2008 to 12.6% in 2012 (Figure 3.3). 
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Note: Gaps in the line indicate a change in definition; direct comparison of trends on either side of these areas is not recommended. 
Source: AIHW analysis of state and territory cervical screening register data.  
Figure 3.3: Proportion of women aged 20–69 rescreening early following a negative cervical 
cytology test, 1996 to 2012 cohorts 
Screening behaviour across groups 
Participation in cervical screening not only lessens an individual’s risk of cervical cancer, but 
a high proportion of women participating reduces the overall incidence and burden of the 
disease in Australia. However, if some population groups participate more or less than 
others, then the benefits from a reduced cervical cancer burden are not shared by all.  
Participation is similar across remoteness areas, with the highest participation of 59.7% in 
Inner regional areas and a relatively high level of participation of 55.4% in Very remote 
locations (Figure 3.4). However, participation in cervical screening shows a clear trend of 
increasing participation with increasing socioeconomic status (Figure 3.5). Participation 
ranged from 52.0% for those of lowest socioeconomic status to 63.8% for the highest 
socioeconomic status group. 
Participation in cervical screening cannot be measured nationally for Aboriginal and Torres 
Strait Islander women as Indigenous status is not included on all pathology forms in all 
states and territories, which is the only source that provides information to cervical screening 
registers. Evidence that is available on the participation in cervical screening by Indigenous 
women suggests that Aboriginal and Torres Strait Islander women are under-screened.  
Coory and others (2002) and Binns and Condon (2006) estimated participation in 
communities with high proportions of Aboriginal and Torres Strait Islander women in 
Queensland and the Northern Territory, respectively. These researchers found that, on 
average, participation by Aboriginal and Torres Strait Islander women was close to 18 
percentage points below that for the respective jurisdiction as a whole, with both studies 
showing considerable variation between communities or regions. 
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Source: AIHW analysis of state and territory cervical screening register data. Data for this figure are available in Table A1.4. 
Figure 3.4: Participation of women aged 20–69, by remoteness area, 2012–2013 
 
  
Source: AIHW analysis of state and territory cervical screening register data. Data for this figure are available in Table A1.5. 
Figure 3.5: Participation of women aged 20–69, by socioeconomic status, 2012–2013 
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It has been recognised that Indigenous women face cultural, linguistic and physical barriers 
to cervical screening (DoHA 2004), and state and territory cervical screening programs have 
developed initiatives to increase participation in cervical screening by Indigenous women. 
These include the employment of Aboriginal and Torres Strait Islander Health Workers, with 
the Australian Government component of the NCSP supporting these through funding the 
development of principles, standards and guidelines for screening Aboriginal and Torres 
Strait Islander women (DoHA 2004). However, without being able to measure participation 
in cervical screening by Indigenous status, it is not known to what extent initiatives are 
reaching their desired aim. 
Progress in this area is being achieved through the Indigenous primary health-care national 
key performance indicators (nKPIs) data collection. Data for this collection are provided to 
the AIHW by primary health-care organisations who receive funding from the Department 
of Health to provide services to Aboriginal and Torres Strait Islander people. 
The purpose of the nKPIs is to improve the delivery of primary health-care services by 
supporting continuous quality improvement activity among service providers. The nKPIs 
also support policy and planning at the national and state and territory level by monitoring 
progress and highlighting areas for improvement (AIHW 2014c).  
The nKPI data collection includes an indicator on women having a cervical screening test at 
2, 3 and 5 year intervals from primary health-care services providing care for Indigenous 
women. As this dataset matures, it will become an increasingly useful dataset for 
understanding the extent of participation by Indigenous women attending these services. 
The nKPI data presented in a recent national report shows that 31% of regular female 
Indigenous clients had a cervical screening test in the 2 years prior to June 2013; 37% had a 
cervical screening test in the previous 3 years; and 43% had a screening test in the previous 5 
years. These proportions had shown some improvements by December 2013, when the 
proportions of Indigenous women who had a cervical screening test increased to 32% in the 
previous 2 years, 40% in the previous 3 years and 46% in the previous 5 years (AIHW 2014c). 
Research is also underway to look at whether linkage of cervical screening to another data 
source which includes Indigenous status (such as hospital data) may allow participation of 
Indigenous women in cervical screening to be estimated (Whop 2014). 
Disparities in participation in cervical screening in women of lower socioeconomic status 
and Indigenous status are likely to have downstream effects on incidence. This will be 
explored more fully in the chapter that explores cervical cancer incidence and mortality. 
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3.2 Characteristics of the screening test  
The screening test of the NCSP is currently 
the Pap test. The objective of a Pap test is to 
sample cells from the transformation zone 
of the cervix (CDHSH 1993)—the site where 
cervical abnormalities and cancer are 
usually found. This is the area between the 
‘original’ and ‘current’ squamocolumnar 
junctions of the cervix, in which the 
squamous cells meet the endocervical cells 
(also known as glandular cells). 
The NCSP developed the National Cervical 
Cytology Coding Sheet based on the 
Australian Modified Bethesda System 2004 
for reporting cervical cytology (NHMRC 
2005). This coding sheet allows pathologists 
to report on both the squamous and 
endocervical components of the cervical 
cytology sample, which together give an 
overall cervical cytology result. This overall 
cytology result may indicate a squamous 
abnormality, an endocervical abnormality, 
or (more rarely) concurrent squamous and 
endocervical abnormalities. 
The squamous cell and endocervical component reporting categories of the National Cervical 
Cytology Coding Sheet are shown in Table 3.1. 
Table 3.1: Cytology reporting categories of the National Cervical Screening Program 
Squamous cell Endocervical component 
SU Unsatisfactory EU Unsatisfactory 
 E0 No endocervical component 
S1 Negative E1 Negative 
S2 Possible low-grade squamous intraepithelial lesion  
S3 Low-grade squamous intraepithelial lesion E2 Atypical endocervical cells of uncertain significance 
S4 Possible high-grade squamous intraepithelial lesion E3 Possible high-grade endocervical glandular lesion 
S5 High-grade squamous intraepithelial lesion E4 Adenocarcinoma in situ 
S6 High-grade squamous intraepithelial lesion with 
  possible microinvasion/ invasion 
E5 Adenocarcinoma in situ with possible microinvasion/ 
  invasion 
S7 Squamous cell carcinoma E6 Adenocarcinoma 
Note: There is a further endocervical component result of E- that has been omitted since this code indicates a vaginal vault smear,  
which is not included in the cervical cytology results presented. 
Under the current NCSP, most Pap tests will disclose a negative cervical cytology result, 
meaning that no abnormality is present. This continued to be the case in 2013, with 92% of 
the more than 2.1 million tests performed that year for women aged 20–69 being negative for 
abnormalities.  
Figure 3.6: Anatomy of the cells of the cervix 
© National Cancer Institute 2013. 
Source: <http://visualsonline.cancer.gov>. 
Reproduced with permission of the copyright owner. 
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A certain proportion of Pap tests contain abnormal cells, this being influenced by the 
underlying prevalence of disease in the population. In 2013, for every 100 Pap tests there 
were 5.8 abnormalities detected—4.4 low-grade and 1.4 high-grade. The delivery of the HPV 
vaccination during school years is expected to reduce the number of abnormalities as these 
girls move into the screening cohort. 
An indication of quality is the proportion of Pap tests that are unsatisfactory—those from 
which the pathologist is unable to determine a clear result. This may be due to too few or too 
many cells, or to the presence of blood or other factors obscuring the cells, or to poor staining 
or preservation (note that the absence of an endocervical component is not considered 
sufficient grounds to deem a cervical cytology sample unsatisfactory (NPAAC 2006)). An 
unsatisfactory Pap test needs to be repeated, so it is desirable that these be minimised. In 
2013, the proportion of Pap tests that were unsatisfactory remained at the low level of 2.2%. 
High-quality cytology is of such importance to the NCSP that there are standards to monitor 
the quality of all laboratories in Australia that report cervical cytology. The National 
Pathology Accreditation Advisory Council (NPAAC) Performance measures for Australian 
laboratories reporting cervical cytology (NPAAC 2006) include standards for unsatisfactory 
cytology and for the detection of abnormalities. These performance measures have been 
calculated as crude rates using data supplied for this report, and are shown in Table 3.2.  
Table 3.2: NPAAC performance measures calculated using NCSP data supplied for Cervical 
screening in Australia 2012–2013 
NPAAC Measure Definition Recommended standard Calculated value 
Performance 
measure 1 
Proportion of specimens reported 
as unsatisfactory 
Between 0.5% and 5.0% of all 
specimens reported as unsatisfactory 
2.2% 
 
Performance 
measure 2b 
(i)  Proportion of specimens 
reported as definite and possible 
high-grade abnormality 
(i)  Not less than 0.7% reported as 
definite or possible high-grade 
abnormality 
(i) 1.4% 
 (ii)  Proportion of specimens 
reported as abnormal 
(ii) Not more than 14.0% reported as 
abnormal 
(ii) 5.8% 
Performance 
measure 3a 
Proportion of cytology specimens 
reported as a definite high-grade 
intraepithelial abnormality where 
cervical histology, taken within 6 
months, confirms the abnormality 
as high-grade intraepithelial 
abnormality or malignancy. 
Not less than 65% of cytology 
specimens with a definite cytological 
prediction of a high-grade 
intraepithelial abnormality are 
confirmed on cervical histology, 
performed within 6 months, as having 
a high-grade intraepithelial 
abnormality or malignancy 
Squamous cytology 
and histology = 78.8% 
(10,648/13,506) 
Endocervical cytology 
and histology = 90.0% 
(216/240) 
Performance 
measure 3b 
Proportion of cytology specimens 
reported as a possible high-grade 
intraepithelial abnormality where 
cervical histology, taken within 6 
months, confirms the abnormality 
as high-grade intraepithelial 
abnormality or malignancy 
Not less than 33% of cytology 
specimens with a cytological 
prediction of a possible high-grade 
intraepithelial abnormality are 
confirmed on cervical histology, 
which is performed within 6 months, 
as having a high-grade intraepithelial 
abnormality or malignancy 
Squamous cytology 
and histology = 52.6% 
(4,986/9,504)  
Endocervical cytology 
and histology = 56.1% 
(143/255) 
Source: AIHW analysis of state and territory cervical screening register data. 
A trend of potential concern is the number of Pap tests for which no endocervical component 
was collected, which continues to increase disproportionately to the increase in the number 
of cytology tests. While the increase in the number of cytology tests for women aged 20–69 
from 2006 to 2013 was 6.7%, there was a 25.7% increase in the number of cytology tests with 
no endocervical component over the same period (from 387,918 to 487,633). This is reflected 
in the steady increase in the proportion of cytology tests with no endocervical component, 
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from 19.1% in 2006 to 22.5% in 2013 for women aged 20–69. This trend holds after age-
standardisation—from 19.5% in 2006 to 22.5% of cytology tests in 2013. 
Cytology tests 
 
Negative cytology 
 
Unsatisfactory cytology 
 
Cytology with no endocervical component 
 
Low-grade abnormalities 
 
High-grade abnormalities 
 
Source: AIHW analysis of state and territory cervical screening register data. Data for these figures are available in tables A3.2, A3.4, A3.7, A3.10, 
A3.13 and A3.14.  
Figure 3.7: Age-distribution of cervical cytology (all cytology, negative cytology, unsatisfactory 
cytology, cytology with no endocervical component, low-grade abnormalities detected by cytology 
and high-grade cytology detected by cytology), 2013.  
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The 2007–2009 National Cancer Prevention Policy of Cancer Council Australia (Cancer 
Council Australia 2007) states that ‘presence of an endocervical component in 80% of Pap 
tests is generally considered acceptable’. In this context, the 2013 rate of 22.5%, which 
indicates the presence of an endocervical component in 77.5% of cytology tests, is slightly 
outside this desired range.  
An endocervical component is difficult to collect in women—just 2% of women older than 64 
have a transformation zone located on the ectocervix (Autier et al. 1996) due to the 
movement of the transformation zone with age. As sampling of the transformation zone is 
required for endocervical cells to be present in a cervical cytology sample, a transformation 
zone high up in the endocervical canal is likely to be more difficult to sample than a 
transformation zone on the ectocervix. This does not explain, however, the increase in the 
proportion of cytology with no endocervical component across all age groups, including 
younger women who are likely to have a transformation zone located on the ectocervix. 
The accuracy of cytology 
Much about the screening test of the NCSP can be learned by examining how well the 
cytology ‘prediction’ matches the histology finding or ‘truth’. Cervical cytology can only be 
seen as a prediction, as a screening test is not intended to be diagnostic, but aims to identify 
people who are more likely to have a cervical abnormality or cervical cancer, and therefore 
require further investigation from diagnostic tests. With this in mind, where cytology is 
followed by histology (either to confirm the presence or absence of disease as predicted by 
the cytology sample, or for other clinical reasons such as to investigate symptoms even in the 
absence of predicted disease), correlation between the cytology prediction and the histology 
finding allows the accuracy of cytological predictions to be assessed. This allows a better 
understanding of the characteristics of the NCSP screening test.  
Follow-up of cytology tests should be in accordance with the NHMRC Screening to prevent 
cervical cancer: guidelines for the management of asymptomatic women with screen detected 
abnormalities (NHMRC 2005), which means that most histology will occur after a cytology 
result of ‘high-grade’ or ‘cancer’. There will be exceptions, however, and these guidelines do 
not cover management of symptomatic women. 
A complete assessment of cytology would require all cytology results (including negative) to 
be followed up by histology, but this is neither feasible nor desirable (it would be unethical 
to require all women who have a Pap test to also undergo a more invasive biopsy). Rather, 
this assessment is restricted to cytology and histology results available on cervical screening 
registers, and is intended to provide key measures that can be monitored annually to inform 
the NCSP of any early indications of alterations to the predictive ability of cervical cytology. 
Correlation between squamous cytology reporting categories and any squamous histology 
that was performed within 6 months is shown in Figure 3.8 and correlation between 
endocervical cytology reporting categories and any endocervical histology performed within 
6 months is shown in Figure 3.9. These do not include cytology tests not followed by 
histology, for which we cannot know the true disease state. 
From Figure 3.8 it can be seen that squamous cytology is generally a good predictor of the 
histology finding; possible high-grade cytology is usually found to be high-grade, and high-
grade cytology almost always found to be high-grade, with squamous cell carcinoma 
cytology usually found to be squamous cell carcinoma.  
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In real terms, 68.3% of high-grade squamous abnormalities predicted by cytology were 
found to be either a true high-grade squamous abnormality or squamous cell carcinoma. 
This is called ‘positive predictive value’. 
Negative and low-grade abnormalities are not usually followed up with histology, so these 
results should not be considered indicative of all negative and low-grade cytology. Of note, 
almost no predictions of possible low-grade or low-grade cytology were found to be cancer. 
Figure 3.9 shows that endocervical cytology is also a reasonable predictor of the true disease 
state. This is despite abnormalities preceding adenocarcinoma being less well understood 
than are the abnormalities preceding squamous cell carcinoma, and interpretation of 
endocervical cells more difficult (as can be the adequate sampling of these cells). These 
factors all affect the correlation between endocervical cytology and endocervical histology. 
Possible high-grade glandular abnormality cytology was found to be adenocarcinoma in situ 
in a reasonable number of cases, with a cytology prediction of adenocarcinoma in situ or 
adenocarcinoma more likely to be adenocarcinoma in situ or adenocarcinoma, respectively. 
In real terms, 73.0% of high-grade endocervical abnormalities predicted by cytology were 
found to be a true high-grade endocervical abnormality or adenocarcinoma on histology (the 
positive predictive value of a high-grade endocervical cytology result). 
While the cytology category ‘atypical endocervical cells of uncertain significance’ is classified 
as a low-grade cytology abnormality, it is not appropriate to correlate this with any 
particular abnormality, since it is used to indicate that abnormal endocervical cells were 
identified in the sample but that the significance of these is uncertain (meaning that these 
could be indicative of a serious abnormality, or could be associated with a benign change 
such as inflammation). This is reflected in the correlation for this category, with these 
atypical cells sometimes found to be adenocarcinoma in situ, but often found to not be 
associated with any abnormality. 
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 Negative cytology 
 
Possible LSIL cytology 
 
LSIL cytology 
 
Possible HSIL cytology 
 
HSIL cytology 
 
Squamous cell carcinoma cytology 
 
Note: LSIL = low-grade intraepithelial lesion (low-grade abnormality); HSIL = high-grade intraepithelial lesion (high-grade abnormality);  
SCC = squamous cell carcinoma. 
Source: AIHW analysis of state and territory cervical screening register data. Data for these figures are available in Table A.5.2. 
Figure 3.8: Correlation of squamous cytology prediction with squamous histology finding for 
women aged 20–69, cytology performed in 2012.  
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Negative cytology 
 
 
Atypical endocervical cells of uncertain 
significance cytology  
 
Possible high-grade endocervical glandular 
lesion cytology 
 
Adenocarcinoma in situ cytology 
 
 
Adenocarcinoma cytology 
 
 
Note: AIS =adenocarcinoma in situ; AC = adenocarcinoma. 
Source: AIHW analysis of state and territory cervical screening register data. Data for these figures are available in Table A.5.5. 
Figure 3.9: Correlation of endocervical cytology prediction with endocervical histology finding for 
women aged 20–69, cytology performed in 2012.  
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3.3 Detection of high-grade abnormalities 
It was previously thought that the development of cervical cancer involved progression from 
low-grade to moderate-grade to high-grade abnormalities, but it is now understood that  
low-grade and high-grade abnormalities represent different HPV processes. Low-grade 
abnormalities occur as a result of acute HPV infection, most of which will resolve 
spontaneously. High-grade abnormalities are the result of persistent infection with a high-
risk HPV type. Most high-grade abnormalities also regress over time (Raffle et al. 2003), but 
regression takes longer (Cancer Council Australia 2014). A major difference between low-risk 
and high-risk HPV types is that high-risk HPV types integrate their DNA into the host 
genome, which is why these are associated with oncogenic (cancer-causing) changes to the 
cells of the cervix, whereas low-risk HPV types are unable to integrate their DNA into the 
host genome and therefore can only cause low-grade changes to cells (Chhieng & Lui 2011). 
As potential precursors to cervical cancer, detection of high-grade abnormalities through 
cervical screening provides an opportunity for treatment before cancer can develop, thus the 
NCSP aims to detect high-grade abnormalities in line with its broader aim to reduce the 
incidence of cervical cancer. Detection of high-grade abnormalities in this context is by 
histology, not by cytology. This is because cytology is not diagnostic, and may under-call or 
over-call true disease (as visible in the cytology-histology correlation data in Chapter 3.2). 
Histology is the primary diagnostic tool of the NCSP, and confirmation of disease is required 
before any treatment is initiated, both to ensure treatment is appropriate and to avoid 
unnecessary treatment in women where the cytology has predicted disease that is not 
present. While colposcopy is used as part of this process, in Australia it is considered best 
practice to confirm high-grade disease with histology prior to treatment (NHMRC 2005).  
Unlike cytology, which has nationally consistent reporting through the AMBS 2004, state and 
territory cervical screening registers have different coding systems for histology that have 
been mapped to a national histology coding system. The squamous and endocervical 
reporting categories of the NCSP national histology coding system are shown in Table 3.3.  
Table 3.3: Histology reporting categories of the National Cervical Screening Program 
Squamous Endocervical 
HSU Unsatisfactory HEU Unsatisfactory 
HS01 Negative HE1 Negative 
HS02 Low-grade squamous abnormality  HE02 Endocervical atypia 
HS03.1 High-grade squamous abnormality, cervical 
intraepithelial neoplasia (CIN) not otherwise specified (NOS) 
HE03.1 High-grade endocervical abnormality, 
endocervical dysplasia 
HS03.2 High-grade squamous abnormality, CIN II HE03.2 High-grade endocervical abnormality, 
adenocarcinoma in situ 
HS03.3 High-grade squamous abnormality, CIN III  
HS04.1 Squamous cell carcinoma, microinvasive HE04.1 Adenocarcinoma, microinvasive 
HS04.2 Squamous cell carcinoma, invasive HE04.2 Adenocarcinoma, invasive 
 HE04.3 Adenosquamous carcinoma 
 HE04.4 Carcinoma of the cervix (other) 
Note: there is a further result of HE03.3 to allow the collection of mixed high-grade histology (carcinoma in situ/adenocarcinoma in situ)  
that has been omitted since this category is not included in the cervical histology results presented. 
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The high-grade abnormality detection rate of the NCSP is the number of women with a  
high-grade abnormality detected by histology per 1,000 women screened. High-grade 
abnormalities of the cervix include cervical intraepithelial neoplasia (CIN) that has been 
graded as moderate (CIN II) or severe (CIN III), or for which the grade has not been 
specified, as well as endocervical dysplasia and adenocarcinoma in situ. 
In 2013, there were 17,609 women with a high-grade abnormality detected by histology, 
which equates to 8.5 women with a high-grade abnormality detected by histology per 1,000 
women screened for women aged 20–69. This means that, for every 1,000 women screened, 
between 8 and 9 had a high-grade abnormality found, providing an opportunity for 
treatment before possible progression to cervical cancer. 
The number of women aged 20–69 with a high-grade abnormality detected by histology per 
1,000 women screened, after remaining at approximately 7.7 for all years from 2005 to 2007, 
increased to above 8 in 2008, where it remained from 2008 to 2013. It is not entirely clear why 
there has been an increase in high-grade abnormality detection, (primarily due to a modest 
increase in women aged 25–39), and there may be various contributing factors. These may 
include a change in classification of abnormalities as a result of the change in management 
guidelines in 2006 (for instance if a pathologist is uncertain they may be more inclined to 
classify an abnormality as high-grade because these are monitored more conservatively),  
or the increased use of p16 immunohistochemistry which can assist in the confirmation of 
high-grade abnormalities, or other as-yet unidentified factors. 
 
Source: AIHW analysis of state and territory cervical screening register data. Data for these figure are available in Table A4.8. 
Figure 3.10: High-grade abnormality detection rate by age, 2007, 2012 and 2013 
In contrast with the overall trend of increasing detection over time, there has been a steady 
decline in high-grade abnormality detection in younger women. In those under 20, this 
decrease commenced from 2007, falling from 11.6 in that year to 5.7 women with high-grade 
histology per 1,000 women screened in 2013. More recently, between 2010 and 2013, there 
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latter trend notably changed the historical peak age of high-grade histological abnormalities 
from women aged 20–24, to women aged 25–29.  
The decrease in high-grade abnormalities in younger women is likely to be due to younger 
girls vaccinated against HPV during the ‘school-based’ or ‘catch-up’ program, who are 
expected to experience fewer abnormalities (a trend noted by Brotherton and others (2011) 
and Gertig and others (2013)). Visible in the under 20 age group several years ago, this is 
now clearly contributing to the 20–24 age group rate in 2013. 
Looking in more detail at the change in the high-grade detection rate by age, using the  
3 years 2004–2006 as the pre-vaccination comparator, the decrease in women aged under 20 
was small but perceptible from 2007, the first year of the National HPV Vaccination Program 
(although the decrease in 2007 could be just natural variation). It has become larger with 
each passing year, to reach a decrease of 7.9 women with a high-grade abnormality detected 
per 1,000 women screened by 2013, the latest data available (Table 3.4).  
For women aged 20–24, this decrease begins in 2011, falling further in 2012 and 2013 to reach 
a decrease of 5.1 (Table 3.4). Older age groups are unaffected, as sufficient time has not yet 
passed for girls vaccinated from 2007 to have moved into age groups beyond 20–24.  
This trend is illustrated in Figure 3.11. 
Table 3.4: Change in high-grade abnormality detection per 1,000 women screened since 2004–2006 
Age group 2004–2006 2007 2008 2009 2010 2011 2012 2013 
<20 13.6 -2.0 -2.8 -4.7 -5.8 -6.5 -7.3 -7.9 
20–24 20.1 -1.2 1.2 -0.2 -0.5 -2.7 -4.3 -5.1 
25–29 17.7 0.1 1.6 1.3 2.2 1.8 2.3 2.6 
30–34 11.6 -0.1 1.1 1.2 2.1 2.4 2.2 2.9 
Note: Change from the 2004–2006 data in bold is shown for age groups <20 to 30–34 from 2007 to 2013. A negative symbol indicates that the 
change is a decrease; no symbol indicates that the change is an increase. 
Source: AIHW analysis of state and territory cervical screening register data.  
To gain further information as to which abnormalities are contributing to this trend in young 
women, the most common high-grade abnormalities, cervical intraepithelial neoplasia 
graded as moderate (CIN II) and severe (CIN III), have been further analysed as the number 
of these abnormalities per 1,000 women screened, and the results shown in the smaller 
graphs in Figure 3.11. 
From these graphs it can be seen that decreases in both CIN II and CIN III in women under 
the age of 20 have contributed to the overall decrease in high-grade abnormalities detected in 
this age group. In women aged 20–24, although CIN II decreased over all the years shown, it 
is only the decrease in CIN III from 2012 that mirrors the trend in high-grade detection in 
this age group. In women aged 25–29, who have experienced no decrease in high-grade 
detection, CIN II remains relatively stable over these years, while CIN II has increased 
(Figure 3.11). 
Of particular note is that, since 2004–2006, the pattern of CIN II has changed—historically 
CIN II was most frequent in women aged 20–24, but in 2013, the decrease in this age group 
has meant that, for the first time, CIN II was most common in women aged 25–29. In 
contrast, CIN III has always occurred most frequently in women aged 25–29, and recent 
trends have not altered this (Figure 3.11).  
  Cervical screening in Australia 2012–2013 21 
Women with high-grade abnormality detected by histology 
 
CIN II histology 
 
CIN III histology 
 
Note: As some states and territories receive data in a format that does not allow them to distinguish between the histology results of CIN II and 
CIN III, these data are only from those states and territories where CIN II and CIN III can be distinguished. 
Source: AIHW analysis of state and territory cervical screening register data.  
Figure 3.11: High-grade abnormality detection rate, CIN II per 1,000 women screened, and CIN III 
per 1,000 women screened, age groups under 30, 2004–2006 to 2013 
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4 Monitoring cervical screening in 
Australia using AIHW data 
4.1 Incidence of cervical cancer 
Australia has high-quality and virtually complete cancer incidence data. Collected by state 
and territory cancer registries, clinical and demographic data for all cancer cases are 
provided to the AIHW and compiled into the Australian Cancer Database. The latest 
national data available are for new cases diagnosed in 2011. 
In 2011, there were 801 new cases of cervical cancer in Australian women. This is equivalent 
to 7.1 new cases for every 100,000 women in the population, which, when age-standardised 
to allow analysis of trends and differentials, equates to an incidence rate of 6.9 for 2011. 
Of the 801 new cases, 682 were in women aged 20–69, the target population of the NCSP. 
These 682 new cases are equivalent to 9.4 new cases for every 100,000 women in the 
population, or 9.5 per 100,000 women aged 20–69 when age-standardised. 
Cervical cancer over time 
This incidence rate of between 9 and 10 new cases per 100,000 women aged 20–69  
(7 new cases per 100,000 women of all ages) has been steady since 2002, after falling from the 
previous figure of around 18 new cases per year prior to the introduction of the NCSP in 
1991 (Figure 4.1).  
 
Note: Rates age-standardised to the Australian population as at 30 June 2001. 
Source: AIHW Australian Cancer Database 2011. Data for this figure are available in Table A6.1. 
Figure 4.1: Incidence of cervical cancer in women aged 20–69, 1982–2011 
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This decrease is attributed to the success of the NCSP. However, it would be expected that 
some decreases in cervical cancer incidence would be apparent before the commencement of 
the NCSP in 1991, particularly from the late 1980s onwards, as opportunistic cervical 
screening has occurred in Australia since the 1960s, and some states trialled organised 
screening in the years leading up to 1991.  
Cervical cancer types 
While all cervical cancers share the same site code (C53 under ICD 10), there are a number of 
histological subtypes within the category of cervical cancer, with clear differences in clinical 
behaviour (Blomfield & Saville 2008). Histology codes for cancers are collected on the ACD, 
which allows the analysis of trends in cervical cancer incidence for different histological 
types. The histological types presented are based on the histological groupings for cervical 
cancer set out in Chapter 4 of Cancer incidence in five continents volume IX (Curado et al. 2007), 
with histological types characterised by the type of cell in which the cancer originates. Thus 
cervical cancer has been disaggregated into the broad histological types of carcinoma 
(cancers of epithelial origin), sarcoma (cancers originating in connective tissue such as bone, 
muscle and fat), and other specified and unknown malignant neoplasms (unusual cancers 
and cancers too poorly differentiated to be classified). Carcinoma has been further split into 
squamous cell carcinoma (which arises from the squamous cells that cover the outer surface 
of the cervix), adenocarcinoma (which arises from the glandular (columnar) cells in the 
endocervical canal), adenosquamous carcinoma (which contains malignant squamous and 
glandular cells), and other carcinoma.  
The table below differs slightly from that presented in Cancer incidence in five continents 
volume IX (Curado et al. 2007), with other specified and unspecified carcinomas grouped 
together, as are other specified and unspecified malignant neoplasms. Further, 
adenosquamous carcinoma has been listed as a separate group under ‘Carcinoma’ rather 
than included in ‘Other specified carcinoma’, as specified in Cancer incidence in five continents 
volume IX (Curado et al. 2007). The latter change is to allow the carcinoma histological 
groupings to match the cervical cancer types collected by the cervical cytology registries and 
reported under the ‘Histology’ performance indicator. 
Table 4.1: Incidence of cervical cancer in women aged 20–69, by histological type, 2011 
Type of cervical cancer 
New 
cases AS rate 
% of cervical 
cancers 
% of 
carcinomas 
1: Carcinoma 670 9.3 98.2 100.0 
1.1: Squamous cell carcinoma 457 6.4 67.0 68.2 
1.2: Adenocarcinoma 165 2.3 24.2 24.6 
1.3: Adenosquamous carcinoma 26 0.4 3.8 3.9 
1.4: Other specified and unspecified carcinoma 22 0.3 3.2 3.3 
2: Sarcoma 2 0.0 0.3 . . 
3: Other specified and unspecified malignant neoplasm 10 0.0 1.5 . . 
Total 682 9.5 100.0 . . 
Note: Age-standardised (AS) rate is the number of new cases per 100,000 women, age-standardised to the Australian population 
at 30 June 2001.Rates based on less than 20 new cases should be interpreted with caution. 
Source: AIHW Australian Cancer Database 2011. 
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In 2011, of the 682 cervical cancers diagnosed in women aged 20–69, 670 (98.2%) were 
carcinomas, 2 (0.3%) were sarcomas, and 10 (1.5%) were classified as ‘Other and unspecified 
malignant neoplasms’ (Table 4.1). Within the carcinomas, squamous cell carcinoma 
comprised the greatest proportion at 68.2% of all cervical carcinomas, followed by 
adenocarcinomas at 24.6% of cervical carcinomas, and adenosquamous carcinomas at 3.9%, 
with ‘Other and unspecified carcinomas’ comprising 3.3% (Table 4.1). 
Trends in age-standardised incidence for women aged 20–69 for squamous cell carcinoma, 
adenocarcinoma, adenosquamous carcinoma and other carcinomas are shown in Figure 4.2. 
 
Source: AIHW Australian Cancer Database 2011. Data for this figure are available in Table A6.2. 
Figure 4.2: Incidence of carcinoma of the cervix (squamous cell carcinoma, adenocarcinoma, 
adenosquamous carcinoma and other carcinomas) in women aged 20–69, 1982–2011 
Squamous cell carcinoma has shown the most substantial change over this time, decreasing 
from 15.1 new cases per 100,000 women in 1982 to 12.4 in 1991, thereafter halving to 6.4 new 
cases per 100,000 women in 2011 (Figure 4.2). 
In contrast, after an initial decrease from 2.8 new cases per 100,000 women in 1991, the 
incidence of adenocarcinoma has remained at around 2 new cases per 100,000 women 
thereafter (Figure 4.2) (the peak of 3.7 new cases per 100,000 women in 1994 is consistent 
with documented trends in Canada, the United States and the United Kingdom, and is 
thought to represent a cohort effect as a result of increased risk of adenocarcinoma for 
women born in the early 1960s (Blomfield & Saville 2008)). Incidence trends of 
adenosquamous and other carcinomas are more difficult to ascertain due to small numbers. 
From these data it is clear that the observed decrease in cervical cancer incidence since the 
introduction of the NCSP in 1991 does not apply equally to all histological types of cervical 
cancer. The trend in squamous cell carcinomas illustrates the success of the NCSP in 
preventing these histological subtypes of cervical cancer through the detection of high-grade 
squamous abnormalities, with these readily identified by repeated cervical cytology 
(Blomfield & Saville 2008). As a result, squamous cell carcinomas now comprise 67% of 
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cervical cancers, much reduced from its historical proportion of 95% (Blomfield & Saville 
2008).  
In contrast, adenocarcinomas have not been reduced to the same degree as squamous cell 
carcinomas by cervical screening, with these glandular carcinomas now comprising a quarter 
of all cervical cancers—previously this was proportionately a rarer disease. The inability of 
cervical screening to reduce glandular cancers below the level reached a decade ago is 
recognised as a reflection of the difficulties in sampling glandular cells (Sasieni et al. 2009), 
with cervical cytology less effective at identifying glandular abnormalities (Blomfield & 
Saville 2008). Further, the cytological interpretation of abnormal glandular cells that are 
sampled (which occur much more infrequently than squamous abnormalities) is more 
difficult, and the progression from glandular abnormality to adenocarcinoma is not well 
characterised (Sasieni et al. 2009; Wang et al. 2006). 
It is also important to realise that some cervical cancers do not have a precancerous stage, 
and therefore are simply unable to be detected—so their incidence is not affected by cervical 
screening. These tend to be rare but aggressive cancers such as neuroendocrine carcinoma of 
the cervix, the two most aggressive types being small cell neuroendocrine carcinoma and 
large cell neuroendocrine carcinoma, neither of which appear to possess a preinvasive stage 
(Necervix.com 2014). 
Cervical cancer across groups 
Incidence for population groups is presented for 2005–2009 (or 2006–2009 in the case of 
socioeconomic status) rather than for 2007–2011, due to the projection of 2010 and 2011 data 
for NSW and the ACT in the 2011 Australian Cancer Database (ACD) (see Appendix C for 
further information). 
Incidence of cervical cancer in 2005–2009 did not differ between Major cities and Inner and 
outer regional areas, being 9.0 and 9.3 new cases per 100,000 women, respectively. Incidence 
in Remote and very remote areas, however, was significantly higher than incidence in Major 
cities and Inner and outer regional areas at 12.7 new cases per 100,000 women (Figure 4.3). 
Higher incidence in Remote and very remote areas is likely to be related to the proportionately 
high number of Indigenous women living in these areas, since Indigenous women have 
more than twice the incidence of cervical cancer (see Figure 4.4). 
In 2006–2009, incidence was relatively similar across the 4 groups of lowest socioeconomic 
status, ranging between 9 and 10 new cases per 100,000 women, but was lower for women 
residing in areas of highest socioeconomic status at 7.4 new cases per 100,000 women  
(Figure 4.3). 
An estimated 50% of cervical cancers occur in women who have never been screened, with a 
further 28% in women who are lapsed screeners (that is, hadn’t had a Pap test in the 2.5 years 
prior to their cancer diagnosis) (VCCR 2012). Therefore it is reasonable to expect that cervical 
cancer incidence patterns may to some degree follow participation patterns.  
This appears to be true to some degree, with a tendency for both incidence rates to be higher 
in Very remote areas and areas of lowest socioeconomic status, identified in analyses of 
screening behaviour earlier in this report as having lower rates of participation in cervical 
screening.  
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Note: Rates age-standardised to the Australian population as at 30 June 2001. 
Source: AIHW Australian Cancer Database 2011. Data for this figure, including 95% confidence intervals, are available in tables A6.5 and A6.6. 
Figure 4.3: Incidence of cervical cancer in women aged 20–69, by remoteness area, 2005–2009 and by 
socioeconomic status, 2006–2009 
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The collection of reliable information by the state and territory cancer registries on the 
Indigenous status of individuals diagnosed with cancer is problematic. This is because 
primary cancer diagnosis information is sourced from pathology forms which currently do 
not record information on Indigenous status in most states and territories. The registries 
therefore collect information on the Indigenous status of individuals from additional sources 
such as hospital records and death records, which affects the completeness of these data. 
This means that reliable national data on the incidence of cancer for Aboriginal and Torres 
Strait Islander Australians are not available, because in some jurisdictions the level of 
identification of Indigenous status is not considered sufficient to enable analysis. In this 
report, data for 4 states and territories—New South Wales, Queensland, Western Australia 
and the Northern Territory—are considered of sufficient quality, and were used to examine 
the incidence of cervical cancer by Indigenous status. While the majority (around 85%) of 
Australian Aboriginal and Torres Strait Islander people reside in these 4 jurisdictions, the 
degree to which data for these jurisdictions are representative of all Aboriginal and Torres 
Strait Islander people is unknown. 
It was found that, over the 5-year period 2005–2009, Aboriginal and Torres Strait Islander 
women aged 20–69 in New South Wales, Queensland, Western Australia and the Northern 
Territory had a significantly higher incidence rate of cervical cancer when compared with 
non-Indigenous women, at 19.5 new cases compared with 8.7 new cases per 100,000 women 
(Figure 4.4).  
 
 
Note: Rates age-standardised to the Australian population as at 30 June 2001. 
Source: AIHW Australian Cancer Database 2011. Data for this figure, including 95% confidence intervals, are available in Table A6.7. 
Figure 4.4: Incidence of cervical cancer in women aged 20–69 (New South Wales, Queensland, 
Western Australia, and Northern Territory), by Indigenous status, 2005–2009 
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4.2 Mortality from cervical cancer 
Similar to incidence data, Australia has high-quality and virtually complete mortality data. 
The mortality data used here were provided by the Registries of Births, Deaths and 
Marriages and the National Coronial Information System and coded by the Australian 
Bureau of Statistics (ABS). These data are maintained at the AIHW in the National Mortality 
Database. The latest national data available are for deaths in 2012. 
In 2012, there were 226 deaths from cervical cancer in Australian women. This is equivalent 
to 2.0 deaths for every 100,000 women in the population, which, when age-standardised to 
allow analysis of trends and differentials, equates to a mortality rate of 1.8 for 2012. 
Of the 226 deaths, 143 were in women aged 20–69, the target population of the NCSP. These 
143 deaths are equivalent to 1.9 deaths for every 100,000 women in the population, or 1.8 per 
100,000 women aged 20–69 when age-standardised. 
Cervical cancer deaths over time 
Mortality from cervical cancer has decreased over time, with this decrease evident prior to 
the introduction of the NCSP in 1991 (from 5.5 deaths per 100,000 women in 1982 to 4.8 
deaths in 1990). With opportunistic cervical screening occurring in Australia since the 1960s, 
some decreases in mortality are to be expected prior to the commencement of the NCSP.  
 
Notes  
1. Deaths from 1982–2011 were derived by year of death; deaths in 2012 were derived by year of registration of death. Deaths registered in 
2009 and earlier are based on the final version of cause-of-death data; deaths registered in 2011 and 2012 are based on revised and 
preliminary versions, respectively, and are subject to further revision by the ABS. 
2. Rates age-standardised to the Australian population as at 30 June 2001. 
Source: AIHW National Mortality Database. Data for this figure are available in Table A7.1. 
Figure 4.5: Mortality from cervical cancer in women aged 20–69, 1982–2012 
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Mortality halved between 1991 and 2012, from 4.0 to 1.8 deaths per 100,000 women for 
women aged 20–69 and women of all ages. This historic low of around 2 deaths per 100,000 
women has been stable since 2002 (Figure 4.5). 
Cervical cancer deaths across groups 
Mortality in 2008–2012 in Major cities was similar to that in Inner and outer regional areas  
(1.8 and 2.2 deaths per 100,000 women, respectively), whereas mortality in Remote and very 
remote areas was higher, at 3.4 deaths per 100,000 women (Figure 4.6). 
 
Notes  
1. Deaths from 2008–2011 were derived by year of death; deaths in 2012 were derived by year of registration of death. Deaths registered in 
2010 and earlier are based on the final version of cause-of-death data; deaths registered in 2011 and 2012 are based on revised and 
preliminary versions, respectively, and are subject to further revision by the ABS. 
2.  Rates age-standardised to the Australian population as at 30 June 2001. 
Source: AIHW National Mortality Database. Data for this figure, including 95% confidence intervals, are available in Table A7.4. 
Figure 4.6: Mortality from cervical cancer in women aged 20–69, by remoteness area, 2008–2012 
Similar to incidence, higher mortality in Remote and very remote areas is likely be related to the 
proportionately high number of Indigenous women living in these areas, since Indigenous 
women experience greater mortality from cervical cancer (see Figure 4.7). 
Information on Indigenous status in the AIHW National Mortality Database is considered to 
be adequate for reporting for 5 jurisdictions—New South Wales, Queensland, Western 
Australia, South Australia and the Northern Territory. The majority (around 90%) of 
Aboriginal and Torres Strait Islander people reside in these 5 jurisdictions.  
In 2008–2012, the mortality rate from cervical cancer was significantly higher in Aboriginal 
and Torres Strait Islander women aged 20–69 in New South Wales, Queensland, Western 
Australia, South Australia and the Northern Territory combined at 7.7 deaths per 100,000 
women compared with non-Indigenous women from these states and territories of 1.9 deaths 
per 100,000 women (Figure 4.7). This mirrors the incidence results for Aboriginal and Torres 
Strait Islander women. 
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Notes  
1. Deaths from 2008–2011 are derived from year of death; deaths in 2012 are derived from year of registration. Deaths registered in 2010 and 
earlier are based on the final version of cause-of-death data; deaths registered in 2011 and 2012 are based on revised and preliminary 
versions, respectively, and are subject to further revision by the ABS.  
2.  Rates age-standardised to the Australian population as at 30 June 2001. 
Source: AIHW National Mortality Database. Data for this figure, including 95% confidence intervals, are available in Table A7.5. 
Figure 4.7: Mortality from cervical cancer in women aged 20–69 (New South Wales, Queensland, 
Western Australia, South Australia and Northern Territory), by Indigenous status, 2008–2012 
 
While participation in cervical screening has a direct effect on the incidence of cervical 
cancer, additional factors come into play for mortality from cervical cancer, such as stage of 
cancer at diagnosis, and treatment. 
Therefore, while it is true that the population groups with the lowest rates of participation in 
cervical screening also have the highest mortality rates, and that this is in part because these 
groups experience higher cervical cancer incidence rates, these trends are confounded by the 
potential issues around access to medical treatment in the more remote areas of Australia, 
and for Aboriginal and Torres Strait Islander women. 
This may explain why trends noted in the cervical cancer incidence chapter are more 
pronounced, with mortality in women residing in Remote and very remote areas being 3.4 
deaths per 100,000 women, compared with 1.8 in Major cities (Figure 4.6). Also, mortality 
from cervical cancer in Aboriginal and Torres Strait Islander women was 4 times that of non-
Indigenous women, at 7.7 deaths per 100,000 women compared with 1.9 deaths (Figure 4.7). 
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5 Monitoring other aspects of cervical 
screening in Australia 
5.1 Monitoring the safety of cervical screening 
management guidelines 
Guidelines enable practitioners and clinicians to manage the 110,000 abnormalities detected 
each year according to evidence-based information which guides best practice. The National 
Health and Medical Research Council’s (NHMRC) Screening to prevent cervical cancer: 
Guidelines for the management of asymptomatic women with screen detected abnormalities  
(NHMRC 2005) provides recommendations for the management of women with an 
abnormal Pap test result. They enable practitioners and clinicians to manage these 110,000 
abnormalities detected each year according to evidence-based information which guides best 
practice. 
The latest guidelines were approved in June 2005 and implemented from 3 July 2006, and 
replaced the previous 1994 guidelines. Formulated in line with the NHMRC standards for 
clinical practice guidelines available at that time, these guidelines are based on 
epidemiological and scientific evidence and a new understanding of the role of HPV in 
cervical cancer. 
The 2005 NHMRC Guidelines included management recommendations that were 
significantly different to the previous 1994 guidelines. They included: 
• changed recommendations for the management of women with a low-grade squamous 
abnormality (possible or definite low-grade squamous intraepithelial lesion) on cytology, 
with most women with this result recommended to have a repeat Pap test in 12 months 
• a new management approach for women treated for high-grade intraepithelial disease, 
recommending that they now undergo a ‘test of cure’ process, whereby cervical cytology 
and HPV tests are conducted at 12-month intervals and if both are negative on 2 
consecutive occasions, the woman is returned to 2-yearly screening. 
As these were significant changes to the way women are managed, in late 2005 a Safety 
Monitoring Committee (SMC) was established to monitor the safety of these 
recommendations and provide timely review of policy as needed.  
In 2013 the Report on monitoring activities of the National Cervical Screening Program Safety 
Monitoring Committee (AIHW 2013b) was published. It demonstrated that the change in 
management for women with a low-grade Pap test result had not led to an increase in 
cervical cancer and that women who complete ‘test of cure’ after being treated for a high-
grade cervical biopsy result had a very low rate of subsequent high-grade biopsy results, and 
no incidents of subsequent cervical cancer. These, along with other evidence, led the SMC to 
conclude that the new guidelines had not led to an increase in cervical cancer in the 7 years 
since they were introduced. 
The SMC was disbanded in 2014, but the safety monitoring of the guidelines is ongoing. 
The following results are based on data to 31 December 2013. Detailed methodology is 
described in Report on monitoring activities of the National Cervical Screening Program Safety 
Monitoring Committee (AIHW 2013b). 
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The proportional hazard ratio calculated between the baseline and ongoing low-grade 
cytology cohorts with 2 years follow-up was 0.92 (95% CI 0.74–1.16). This is not statistically 
significantly different to 1, indicating no statistically significant change in the risk of cancer 
after a low-grade squamous cytology under the current guidelines, compared to the previous 
guidelines. The proportional hazard ratio was also calculated for Parameter 1 with 5 years 
follow-up, and found to be 1.01 (95% CI 0.83–1.23). These data are shown in Table 5.1.  
Table 5.1: Summary of low-grade cohort data, baseline and ongoing, 2 and 5 years follow-up 
 Baseline Ongoing Hazard ratio 
2 years follow-up    
  Low-grade abnormalities 512,315 539,390 0.92 
  Total person-time in cohort (years) 680,683 781,587 (0.74–1.16) 
  Cancers in cohort 158 157  
5 years follow-up    
  Low-grade abnormalities 512,315 539,390 1.01 
  Total person-time in cohort (years) 1,042,976 1,349,246 (0.83–1.23) 
  Cancers in cohort 188 223  
Source: AIHW analysis of state and territory cervical screening register data.  
 
Two additional analyses were undertaken to look at incidence of cervical cancer after a 
histologically confirmed high-grade abnormality. 
First, a comparison of cervical cancers that occurred in the 5 years following a 12-month 
clinical management period, immediately following a histologically confirmed high-grade 
abnormality was made. The numbers were small, with 31 cancers found for the baseline 
period and 55 following introduction of the new guidelines. Proportional hazards regression 
did not reveal this to be a statistically significant increase, and, as there are no management 
changes between the previous guidelines and the new guidelines, this analysis does not 
address the safety of new management practices.  
The second analysis assessed cervical cancer incidence after women had completed ‘test of 
cure’. It is believed that HPV test data are incomplete, and that, coupled with possible non-
compliance of general practitioners, has led to the number of women who have completed 
‘test of cure’ being an underestimate of the true number. Nonetheless, it is encouraging that, 
of the more than seven thousand women aged 20–69 who are known to have completed test 
of cure after a treated histologically-confirmed high-grade abnormality, none were found to 
have developed cervical cancer. 
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5.2 Expenditure on cervical screening 
Expenditure on Australia’s cancer screening programs  
In Australia, there are three cancers for which screening is recommended—breast, cervical 
and bowel. Each cancer has a national screening program, with both Australian government 
and state and territory government components.  
The Australian government provides funding to the states and territories for public health 
services through National Health Reform Payments (known as National Specific Purpose 
Payments prior to 1 July 2012) and National Partnership Payments. State and territory 
governments have full discretion over the application of National Health Reform Payments 
for public health funding, including the amount expended on BreastScreen Australia and the 
NCSP. The funding for the National Bowel Cancer Screening Program is through a specific 
National Partnership Payment.  
In addition to the funding provided by the Australian government, state and territory 
governments also contribute funding towards these programs. 
Table 5.2 shows expenditure for the three national cancer screening programs (expenditure 
by Australian and state and territory governments combined), as well as total expenditure on 
cancer screening for the 2012–13 financial year. 
Table 5.2: Government funding for cancer screening programs, 2012–13, $ million 
Screening program Expenditure 2012–13 
BreastScreen Australia(a) 204.9 
National Cervical Screening Program(b) 89.3 
National Bowel Cancer Screening Program(c) 32.9 
Total 327.1 
(a) Excludes mammography for breast cancer screening that occurs outside BreastScreen Australia. 
(b) Excludes the proportion of the costs associated with GP, specialist and nurse attendances that would have been for Pap smears. 
(c) Excludes MBS flow-on costs as well as bowel screening that occurs outside the National Bowel Cancer Screening Program. 
Note: These expenditure data only include recurrent expenditure; health infrastructure payments for cancer have been excluded as well as any 
health workforce expenditure. 
Sources: AIHW Health expenditure database; Medicare Australia Statistics. 
Expenditure on cervical screening 
In 2012–13 an estimated $89.3 million was spent on cervical screening in Australia.  
This cannot be compared with the expenditure of $125.2 million reported for cervical 
screening for 2008–09, as this latter figure included an estimate for the proportion of the costs 
associated with GP, specialist and nurse attendances for Pap tests (AIHW 2013b)—an 
estimate no longer included in the expenditure data. This limits the comparability of data. 
Of the $89.3 million spent on cervical screening, $35 million—more than a third—was spent 
on Medicare Benefit Schedule (MBS) items for cervical screening (MBS items 73053 and 
73922). Other cervical screening expenditure by the Australia government included Practice 
Incentives Program (PIP) incentive payments totalling $4.6 million, and $8.1 million to assist 
Victoria in funding the Victorian Cytology Service (which processes smears taken by health 
professionals other than General Practitioners, such as Aboriginal health workers and nurse 
Pap test providers, which are not eligible for funding under the Medicare Benefits Schedule). 
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Appendix A: Supporting data tables  
A.1 Participation 
Table A1.1: Number and age-standardised rate of women aged 20–69 participating in the National 
Cervical Screening Program, 1996–1997 to 2012–2013 
Reporting period Participants(b) Adjusted population(c) AS rate(d) 
1996–1997(a) 2,563,107 4,171,326 61.2 
1997–1998(a) 2,653,504 4,210,148 62.8 
1998–1999(a) 2,716,364 4,246,280 63.7 
1999–2000 3,244,329 5,245,032 61.7 
2000–2001 3,262,931 5,302,865 61.4 
2001–2002 3,296,409 5,365,549 61.4 
2002–2003 3,318,354 5,432,781 61.1 
2003–2004 3,354,519 5,501,337 61.1 
2004–2005 3,407,219 5,738,149 59.4 
2005–2006 3,452,093 5,822,719 59.3 
2006–2007 3,549,524 5,920,032 60.1 
2007–2008 3,599,919 6,035,760 59.8 
2008–2009 3,638,941 6,167,170 59.3 
2009–2010 3,635,929 6,291,062 58.2 
2010–2011 3,641,198 6,396,134 57.3 
2011–2012 3,723,738 6,499,742 57.7 
2012–2013 3,815,705 6,614,886 58.2 
(a) Since the Queensland Health Pap Smear Register began operations in February 1999, Queensland data are excluded from both the 
participant and population data for the 1996–1997, 1997–1998 and 1998–1999 reporting periods. 
(b)  ‘Participants’ are the number of women aged 20–69 screened in each 2-year reporting period. Number of women screened includes all 
women screened in each jurisdiction, not just those women resident in each jurisdiction, with the exception of Victoria and the Australian 
Capital Territory, for which only residents of the jurisdiction (and immediate border residents) are included.  
(c)  ‘Adjusted population’ is the average of the Australian Bureau of Statistics (ABS) estimated resident population for women aged 20–69 for 
the 2 years, adjusted to include only women with an intact cervix using age-specific hysterectomy fractions. Reporting periods 1996–1997 to 
2003–2004 use hysterectomy fractions derived from the 2001 ABS National Health Survey; reporting periods 2004–2005 to 2012–2013 use 
hysterectomy fractions derived from the AIHW National Hospitals Morbidity Database. 
(d)  ‘Age-standardised (AS) rate’ is the number of women aged 20–69 screened in each 2-year reporting period as a percentage of the ABS 
estimated resident population for women aged 20–69, adjusted to include only women with an intact cervix as described above,  
age-standardised to the Australian population at 30 June 2001. 
Note: Rates from 1996–1997 to 2003–2004 cannot be directly compared with rates from 2004–2005 onwards, due to a different source of 
hysterectomy fractions used to adjust the population. 
Source: AIHW analysis of state and territory cervical screening register data. 
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Table A1.2: Participation, by age, 2012–2013  
Age group 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 
Women 341,573 438,781 464,083 457,337 476,866 427,591 402,662 333,473 276,002 197,337 
Crude rate 42.7 52.0 58.1 61.0 62.6 64.5 64.0 61.9 60.4 52.7 
Note: ‘Crude rate’ is the number of women screened in 2012–2013 as a percentage of the ABS estimated resident population for women aged  
20–69, adjusted to include only women with an intact cervix using age-specific hysterectomy fractions derived from the AIHW National Hospitals 
Morbidity Database. 
Source: AIHW analysis of state and territory cervical screening register data. 
Table A1.3: Participation of women aged 20–69, by state and territory, 2012–2013  
State/territory NSW Vic Qld WA SA Tas ACT NT Australia 
Women 1,200,258 1,014,030 742,161 396,874 277,277 81,121 66,211 37,773 3,815,705 
Crude rate 56.9 60.9 56.0 55.5 58.7 57.0 57.0 55.2 57.7 
AS rate 57.4 61.6 56.4 55.9 59.0 57.4 58.0 55.1 58.2 
Notes 
1. Direct comparisons between the states and territories of Australia are not advised due to the substantial differences that exist between the 
jurisdictions, including population, area, geographic structure, policies and other factors. 
2. ‘Age-standardised (AS) rate’ is the number of women screened in 2012–2013 as a percentage of the ABS estimated resident population for 
women aged 20–69, adjusted to include only women with an intact cervix using age-specific hysterectomy fractions derived from the AIHW 
National Hospitals Morbidity Database, age-standardised to the Australian population at 30 June 2001. 
Source: AIHW analysis of state and territory cervical screening register data. 
Table A1.4: Participation of women aged 20–69, by remoteness area, 2012–2013 
Remoteness 
area Major cities 
Inner  
regional 
Outer 
regional Remote Very remote Australia 
Women 2,737,914 677,589 320,224 49,671 29,089 3,815,705 
Crude rate 57.3 59.7 57.5 57.4 54.7 57.7 
AS rate 58.1 59.7 57.5 57.6 55.4 58.2 
Notes  
1. Women were allocated to a remoteness area using their residential postcode according to the Australian Statistical Geography Standard 
(ASGS) for 2011. Caution is required when examining differences across remoteness area (see Appendix C). 
2. ‘Age-standardised (AS) rate’ is the number of women screened in 2012–2013 as a percentage of the ABS estimated resident population for 
women aged 20–69, adjusted to include only women with an intact cervix using age-specific hysterectomy fractions derived from the AIHW 
National Hospitals Morbidity Database, age-standardised to the Australian population at 30 June 2001. 
Source: AIHW analysis of state and territory cervical screening register data. 
Table A1.5: Participation of women aged 20–69, by socioeconomic status, 2012–2013 
Socioeconomic 
status 
1 
(lowest)  
2 3 4 5  
(highest) Australia 
Women 643,723 704,554 761,425 807,028 874,077 3,815,705 
Crude rate 51.6 55.5 56.6 59.1 63.3 57.7 
AS rate 52.0 55.9 57.1 59.6 63.8 58.2 
Notes  
1. Women were allocated to a socioeconomic status using their residential postcode according to the Socio-Economic Indexes for Areas 
(SEIFA) Index of Relative Socio-Economic Disadvantage for 2011. Caution is required when examining differences across socioeconomic 
status (see Appendix C). 
2. ‘Age-standardised (AS) rate’ is the number of women screened in 2012–2013 as a percentage of the ABS estimated resident population for 
women aged 20–69, adjusted to include only women with an intact cervix using age-specific hysterectomy fractions derived from the AIHW 
National Hospitals Morbidity Database, age-standardised to the Australian population at 30 June 2001. 
Source: AIHW analysis of state and territory cervical screening register data. 
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Table A1.6: Participation, by age, over 3 years and 5 years 
Age group 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 
3 years 2011–2013 
Women 442,361 552,717 570,073 566,856 571,778 515,251 471,808 385,094 317,297 219,645 
Crude rate 55.6 66.3 72.6 75.2 76.0 77.5 75.8 72.3 69.7 60.6 
5 years 2009–2013 
Women 583,957 682,859 680,019 684,795 643,138 589,866 512,858 413,929 334,556 229,781 
Crude rate 74.2 83.8 88.9 89.8 87.8 88.3 84.1 79.4 75.0 66.9 
Note: ‘Crude rate’ is the number of women screened as a percentage of the ABS estimated resident population for women aged 20–69, adjusted 
to include only women with an intact cervix using age-specific hysterectomy fractions derived from the AIHW National Hospitals Morbidity 
Database. 
Source: AIHW analysis of state and territory cervical screening register data. 
Table A1.7: Participation of women aged 20–69, by state and territory, over 3 years and 5 years  
State/territory NSW Vic Qld WA SA Tas ACT NT Australia 
3 years 2011–2013 
Crude rate 70.1 73.4 68.3 67.4 72.3 69.5 71.0 69.9 70.3 
AS rate 70.6 74.0 68.6 67.6 72.8 70.0 71.9 69.3 70.8 
5 years 2009–2013 
Crude rate 82.8 85.1 81.8 79.6 84.1 81.0 87.2 87.9 83.0 
AS rate 83.3 85.3 81.7 79.2 84.6 81.9 87.1 85.8 83.2 
Notes 
1. Direct comparisons between the states and territories of Australia are not advised due to the substantial differences that exist between the 
jurisdictions, including population, area, geographic structure, policies and other factors. 
2. ‘Age-standardised (AS) rate’ is the number of women screened as a percentage of the ABS estimated resident population for women aged 
20–69, adjusted to include only women with an intact cervix using age-specific hysterectomy fractions derived from the AIHW National 
Hospitals Morbidity Database, age-standardised to the Australian population at 30 June 2001. 
Source: AIHW analysis of state and territory cervical screening register data. 
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A.2 Rescreening 
Table A2.1: Number and proportion of women aged 20–69  
rescreening early following a negative cervical cytology test,  
by number of early rescreens, 2012 cohort  
Early rescreens Number of women % of women 
0 146,008 87.4  
1 20,375 12.2  
2 629 0.4  
3+ 48 0.0  
Note: Women with a cytological or histological abnormality in the preceding 36 months are excluded the cohort; repeat cytology tests that are a 
valid repeat of an unsatisfactory cytology test are excluded from this count. 
Source: AIHW analysis of state and territory cervical screening register data.  
Table A2.2: Proportion of women aged 20–69 rescreening early following a negative cervical 
cytology test, by state and territory, 2012 cohort  
State/territory NSW Vic Qld WA SA Tas ACT NT Australia 
% 13.5  12.7  12.8  11.8  10.4  10.2  10.1  11.6  12.6  
Source: AIHW analysis of state and territory cervical screening register data.  
Table A2.3: Women aged 20–69 rescreening within 3 months of 27-month cervical screening register 
reminder letter, by state and territory, letters sent in 2012  
State/territory NSW Vic Qld WA SA Tas ACT NT Australia 
No. sent letter 306,730 232,214  189,871  91,311  . .  22,215  20,689  9,927  872,957  
No. rescreened 97,335 78,433  64,343  28,619  . .  8,544  5,963  1,998  285,235  
% 31.7  33.8  33.9  31.3  . .  38.5  28.8  20.1  32.7  
Note: Data are not available for South Australia, which at present does not have a 27-month cervical screening register reminder letter sent to 
women. (These are sent to practitioners, with a 30-month reminder letter sent to women, neither of which are directly comparable.) 
Source: AIHW analysis of state and territory cervical screening register data.  
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A.3 Cytology 
Table A3.1: Number of cytology tests, by age, 2006 to 2013 
Age group 
(years) 2006 2007 2008 2009 2010 2011 2012 2013 
<20 65,189 67,861 63,668 60,813 55,511 56,159 53,323 51,549 
20–24 203,531 215,454 203,540 202,951 192,175 195,602 195,502 196,907 
25–29 235,385 249,461 242,116 249,852 240,510 247,362 251,896 257,726 
30–34 270,412 268,829 258,449 259,995 246,489 253,185 260,357 271,579 
35–39 273,274 283,760 281,047 281,300 264,471 260,198 256,294 259,395 
40–44 259,880 259,723 250,963 252,387 245,041 252,666 261,413 270,965 
45–49 239,884 248,203 243,146 246,688 236,829 235,860 235,597 238,943 
50–54 196,236 201,663 202,073 206,118 205,915 211,883 218,708 225,342 
55–59 163,546 166,087 165,893 168,806 168,579 172,415 179,296 184,872 
60–64 112,240 122,356 129,177 134,622 139,035 144,153 146,935 151,208 
65–69 75,700 77,881 79,390 83,835 86,816 92,294 102,229 109,584 
70+ 30,188 29,925 28,353 28,005 27,750 28,014 28,402 29,752 
All ages 2,125,522 2,191,238 2,147,848 2,175,383 2,109,131 2,149,798 2,189,960 2,247,835 
Ages 20–69 2,030,088 2,093,417 2,055,794 2,086,554 2,025,860 2,065,618 2,108,227 2,166,521 
Source: AIHW analysis of state and territory cervical screening register data.  
Table A3.2: Proportion of cytology tests, by age, 2013  
Age group <20 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70+ 
Crude rate 2.3 8.8 11.5 12.1 11.5 12.1 10.6 10.0 8.2 6.7 4.9 1.3 
Note: ‘Crude rate’ is the number of cytology tests as a proportion of the total number of cytology tests. 
Source: AIHW analysis of state and territory cervical screening register data. 
Table A3.3: Unsatisfactory cytology tests in women aged 20–69, 2006 to 2013 
 2006 2007 2008 2009 2010 2011 2012 2013 
Number 42,720 44,912 43,223 43,104 42,096 42,760 46,192 48,148 
Crude rate 2.1 2.2 2.1 2.1 2.1 2.1 2.2 2.2 
AS rate 2.1 2.2 2.1 2.1 2.1 2.1 2.2 2.2 
Note: ‘Crude rate’ is the number of unsatisfactory cytology tests as a proportion of the total number of cytology tests; ‘age-standardised (AS) 
rate’ is the number of unsatisfactory cytology tests as a proportion of the total number of cytology tests age-standardised to the Australian 
population at 30 June 2001. 
Source: AIHW analysis of state and territory cervical screening register data.  
Table A3.4: Unsatisfactory cytology tests, by age, 2013  
Age group <20 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70+ 
Number 1,360 5,079 6,557 6,455 5,677 5,555 4,477 4,479 4,162 3,448 2,259 778 
Crude rate 2.6 2.6 2.5 2.4 2.2 2.1 1.9 2.0 2.3 2.3 2.1 2.6 
Note: ‘Crude rate’ is the number of unsatisfactory cytology tests as a proportion of the total number of cytology tests. 
Source: AIHW analysis of state and territory cervical screening register data. 
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Table A3.5: Unsatisfactory cytology tests in women aged 20–69, by state and territory, 2013 
 NSW Vic Qld WA SA Tas ACT NT Australia 
Number 13,217 15,381 8,677 4,782 3,616 1,455 704 316 48,148 
Crude rate 1.9 2.7 2.0 2.1 2.3 3.2 1.9 1.4 2.2 
AS rate 1.9 2.7 2.0 2.1 2.3 3.2 1.9 1.4 2.2 
Note: ‘Crude rate’ is the number of unsatisfactory cytology tests as a proportion of the total number of cytology tests; ‘age-standardised (AS) rate’ 
is the number of unsatisfactory cytology tests as a proportion of the total number of cytology tests age-standardised to the Australian population at 
30 June 2001. 
Source: AIHW analysis of state and territory cervical screening register data.  
Table A3.6: Negative cytology tests in women aged 20–69, 2006 to 2013 
 2006 2007 2008 2009 2010 2011 2012 2013 
Number 1,857,552 1,922,592 1,891,705 1,931,682 1,876,881 1,908,291 1,943,563 1,992,544 
Crude rate 91.5 91.8 92.0 92.6 92.6 92.4 92.2 92.0 
AS rate 91.6 91.9 92.1 92.6 92.6 92.3 92.1 91.9 
Note: ‘Crude rate’ is the number of negative cytology tests as a proportion of the total number of cytology tests; ‘age-standardised (AS) rate’ is the 
number of negative cytology tests as a proportion of the total number of cytology tests age-standardised to the Australian population at 30 June 
2001. 
Source: AIHW analysis of state and territory cervical screening register data.  
Table A3.7: Negative cytology tests, by age, 2013  
Age group <20 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70+ 
Number 43,250 165,954 224,720 245,469 239,040 252,203 224,435 213,820 176,309 144,968 105,626 28,193 
Crude rate 83.9 84.3 87.2 90.4 92.2 93.1 93.9 94.9 95.4 95.9 96.4 94.8 
Note: ‘Crude rate’ is the number of negative cytology tests as a proportion of the total number of cytology tests.  
Source: AIHW analysis of state and territory cervical screening register data. 
Table A3.8: Negative cytology tests in women aged 20–69, by state and territory, 2013 
 NSW Vic Qld WA SA Tas ACT NT Australia 
Number 632,338 519,289 395,552 205,049 144,211 41,699 34,559 19,847 1,992,544 
Crude rate 93.0 90.4 92.8 90.2 93.1 92.1 93.6 91.1 92.0 
AS rate 92.9 90.2 92.8 90.5 92.9 91.8 93.8 91.8 91.9 
Note: ‘Crude rate’ is the number of negative cytology tests as a proportion of the total number of cytology tests; ‘age-standardised (AS) rate’ is the 
number of negative cytology tests as a proportion of the total number of cytology tests age-standardised to the Australian population at 30 June 
2001. 
Source: AIHW analysis of state and territory cervical screening register data.  
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Table A3.9: Cytology tests with no endocervical component in women aged 20–69, 2006 to 2013 
 2006 2007 2008 2009 2010 2011 2012 2013 
Number 387,918 406,736 407,942 418,527 424,077 440,411 461,425 487,633 
Crude rate 19.1 19.4 19.8 20.1 20.9 21.3 21.9 22.5 
AS rate 19.5 19.8 20.2 20.3 21.1 21.4 21.9 22.5 
Note: ‘Crude rate’ is the number of cytology tests with no endocervical component as a proportion of the total number of cytology tests;  
‘age-standardised (AS) rate’ is the number of cytology tests with no endocervical component as a proportion of the total number of cytology 
tests age-standardised to the Australian population at 30 June 2001. 
Source: AIHW analysis of state and territory cervical screening register data.  
Table A3.10: Cytology tests with no endocervical component, by age, 2013  
Age 
group 
<20 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70+ 
Number 9,939 37,319 47,435 48,977 47,682 54,656 54,725 57,217 52,990 48,758 37,874 11,584 
Crude 
rate 19.3 19.0 18.4 18.0 18.4 20.2 22.9 25.4 28.7 32.2 34.6 38.9 
Note: ‘Crude rate’ is the number of cytology tests with no endocervical component as a proportion of the total number of cytology tests. 
Source: AIHW analysis of state and territory cervical screening register data. 
Table A3.11: Cytology tests with no endocervical component in women aged 20–69, by state and 
territory, 2013 
 NSW Vic Qld WA SA Tas ACT NT Australia 
Number 133,465 153,663 81,093 55,028 35,944 14,609 8,185 5,646 487,633 
Crude rate 19.6 26.8 19.0 24.2 23.2 32.2 22.2 25.9 22.5 
AS rate 19.6 26.7 19.1 24.8 22.9 31.6 22.5 27.2 22.5 
Note: ‘Crude rate’ is the number of cytology tests with no endocervical component as a proportion of the total number of cytology tests; ‘age-
standardised (AS) rate’ is the number of cytology tests with no endocervical component as a proportion of the total number of cytology tests age-
standardised to the Australian population at 30 June 2001. 
Source: AIHW analysis of state and territory cervical screening register data.  
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Table A3.12: Abnormalities detected by cytology in women aged 20–69, 2006 to 2013 
 2006 2007 2008 2009 2010 2011 2012 2013 
Low-grade abnormalities 
Number 103,841 97,916 92,013 83,933 78,510 84,540 88,845 95,804 
Crude rate 5.1 4.7 4.5 4.0 3.9 4.1 4.3 4.4 
AS rate 5.1 4.6 4.5 4.0 3.9 4.1 4.3 4.5 
High-grade abnormalities 
Number 26,165 28,297 29,176 28,054 28,491 30,253 29,875 30,320 
Crude rate 1.3 1.4 1.4 1.3 1.4 1.5 1.4 1.4 
AS rate 1.3 1.3 1.4 1.3 1.4 1.5 1.4 1.4 
All abnormalities (low-grade, high-grade, and cancer)   
Number 130,234 126,442 121,400 112,188 107,261 115,026 118,953 126,344 
Crude rate 6.4 6.0 5.9 5.4 5.3 5.6 5.8 5.8 
AS rate 6.3 5.9 5.9 5.4 5.3 5.6 5.8 5.9 
Notes 
1. ‘Low-grade abnormalities’ are cytology test results S2, S3 and E2; ‘high-grade abnormalities’ are cytology results S4, S5, S6, E3,  
E4 and E5. All abnormalities are cytology results S2, S3, S4, S5, S6, S7, E2, E3, E4, E5 and E6 (see Table 3.1). 
2. ‘Crude rate’ is the number of low-grade, high-grade, or all abnormalities detected by cytology as a proportion of the total number  
of cytology tests; ‘age-standardised (AS) rate’ is the number of low-grade, high-grade, or all abnormalities detected by cytology as a 
proportion of the total number of cytology tests age-standardised to the Australian population at 30 June 2001. 
3. This is the number of abnormalities detected, not the number of abnormal cytology tests—in a small proportion of cytology tests there may 
be more than one abnormality detected, both of which will be counted. 
Source: AIHW analysis of state and territory cervical screening register data.  
Table A3.13: Low-grade abnormalities detected by cytology, by age, 2013  
Age 
group 
<20 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70+ 
Number 6,211 21,213 18,845 13,730 10,895 10,405 8,143 5,719 3,471 2,131 1,252 539 
Crude 
rate 12.0 10.8 7.3 5.1 4.2 3.8 3.4 2.5 1.9 1.4 1.1 1.8 
Note: ‘Crude rate’ is the number low-grade abnormalities detected by cytology as a proportion of the total number of cytology tests. 
Source: AIHW analysis of state and territory cervical screening register data. 
Table A3.14: High-grade abnormalities detected by cytology, by age, 2013  
Age 
group 
<20 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70+ 
Number 731 4,685 7,697 6,037 3,839 2,836 1,927 1,322 914 651 412 184 
Crude 
rate 1.4 2.4 3.0 2.2 1.5 1.0 0.8 0.6 0.5 0.4 0.4 0.6 
Note: ‘Crude rate’ is the number of high-grade abnormalities detected by cytology as a proportion of the total number of cytology tests. 
Source: AIHW analysis of state and territory cervical screening register data. 
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Table A3.15: Squamous abnormalities detected by cytology in women aged 20–69, by squamous 
category, 2006 to 2013 
Squamous category 2006 2007 2008 2009 2010 2011 2012 2013 
S2 Possible low-grade squamous intraepithelial lesion   
Number 59,788 55,431 54,262 51,147 47,290 43,485 52,007 57,748 
Per 100 cytology tests 2.7 2.6 2.5 2.3 2.1 2.4 2.5 2.7 
% of squamous abnormalities 43.4 43.6 42.8 42.8 41.1 43.6 44.4 46.4 
S3 Low-grade squamous intraepithelial lesion   
Number 47,038 42,502 39,846 35,897 34,311 34,276 36,047 37,136 
Per 100 cytology tests 2.3 2.0 1.9 1.7 1.7 1.7 1.7 1.7 
% of squamous abnormalities 36.8 34.2 33.4 32.5 32.5 30.2 30.7 29.8 
S4 Possible high-grade squamous intraepithelial lesion   
Number 9,456 10,727 11,500 11,494 12,088 13,020 12,848 13,334 
Per 100 cytology tests 0.5 0.5 0.6 0.6 0.6 0.6 0.6 0.6 
% of squamous abnormalities 7.4 8.6 9.6 10.4 11.4 11.5 11.0 10.7 
S5 High-grade squamous intraepithelial lesion   
Number 15,342 16,438 16,491 15,505 15,317 16,117 15,863 15,791 
Per 100 cytology tests 0.8 0.8 0.8 0.7 0.8 0.8 0.8 0.7 
% of squamous abnormalities 12.0 13.2 13.8 14.0 14.5 14.2 13.5 12.7 
S6 High-grade squamous intraepithelial lesion with possible microinvasion/ invasion   
Number 318 316 290 287 313 310 346 317 
Per 100 cytology tests 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
% of squamous abnormalities 0.2 0.3 0.2 0.3 0.3 0.3 0.3 0.3 
S7 Squamous cell carcinoma   
Number 150 154 126 141 178 155 153 142 
Per 100 cytology tests 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
% of squamous abnormalities 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.1 
All squamous abnormalities   
Number 127,735 124,399 119,400 110,614 105,692 113,321 117,264 124,468 
Crude rate 6.3 5.9 5.8 5.3 5.2 5.5 5.6 5.7 
AS rate 6.2 5.8 5.8 5.3 5.3  5.5  5.6  5.8 
Note: ‘Crude rate’ is the number of each squamous abnormality or of all squamous abnormalities combined detected by cytology as a proportion 
of the total number of cytology tests; ‘age-standardised (AS) rate’ is the number of all squamous abnormalities combined detected by cytology as 
a proportion of the total number of cytology tests age-standardised to the Australian population at 30 June 2001. 
Source: AIHW analysis of state and territory cervical screening register data.  
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Table A3.16: Endocervical abnormalities detected by cytology in women aged 20–69, by 
endocervical category, 2006 to 2013 
Endocervical category 2006 2007 2008 2009 2010 2011 2012 2013 
E2 Atypical endocervical cells of uncertain significance   
Number 1,372 1,152 1,020 746 714 821 791 920 
% of cytology tests 0.07 0.06 0.05 0.04 0.04 0.04 0.04 0.04 
% of endocervical abnormalities 54.9 56.4 51.0 47.4 45.5 48.2 46.8 49.0 
E3 Possible high-grade endocervical glandular lesion   
Number 724 510 562 461 435 500 531 540 
% of cytology tests 0.04 0.02 0.03 0.02 0.02 0.02 0.03 0.02 
% of endocervical abnormalities 29.0 25.0 28.1 29.3 27.7 29.3 31.4 28.8 
E4 Adenocarcinoma in situ   
Number 283 277 299 283 305 283 266 307 
% of cytology tests 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.01 
% of endocervical abnormalities 11.3 13.6 15.0 18.0 19.4 16.6 15.7 16.4 
E5 Adenocarcinoma in situ with possible microinvasion/invasion   
Number 42 29 34 24 33 23 21 31 
% of cytology tests 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
% of endocervical abnormalities 1.7 1.4 1.7 1.5 2.1 1.3 1.2 1.7 
E6 Adenocarcinoma   
Number 78 75 85 60 82 78 80 78 
% of cytology tests 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
% of endocervical abnormalities 3.1 3.7 4.3 3.8 5.2 4.6 4.7 4.2 
All endocervical abnormalities   
Number 2,499 2,043 2,000 1,574 1,569 1,705 1,689 1,876 
Crude rate 0.12 0.10 0.10 0.08 0.08 0.08 0.08 0.09 
AS rate 0.12 0.10 0.10 0.07 0.08 0.08 0.08 0.09 
Note: ‘Crude rate’ is the number of each endocervical abnormality or of all endocervical abnormalities combined detected by cytology as a 
proportion of the total number of cytology tests; ‘age-standardised (AS) rate’ is the number of all endocervical abnormalities combined detected by 
cytology as a proportion of the total number of cytology tests age-standardised to the Australian population at 30 June 2001. 
Source: AIHW analysis of state and territory cervical screening register data.  
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A.4 Histology 
Table A4.1: Number of histology tests, by age, 2006 to 2013  
Age group 
(years) 2006 2007 2008 2009 2010 2011 2012 2013 
<20 2,909 2,296 2,089 1,689 1,454 1,380 1,257 1,177 
20–24 12,655 11,967 12,136 11,187 10,519 10,089 9,636 9,229 
25–29 12,490 12,364 12,621 12,625 12,690 12,940 13,517 14,097 
30–34 10,448 9,975 9,989 10,009 9,839 10,635 10,908 11,752 
35–39 8,716 8,819 9,037 8,985 8,753 9,259 9,703 9,885 
40–44 8,671 8,309 8,249 8,280 8,265 9,218 9,920 10,637 
45–49 7,878 8,107 8,202 8,348 8,584 8,681 8,985 9,657 
50–54 5,043 5,290 5,382 5,623 5,742 6,259 6,637 7,105 
55–59 3,318 3,271 3,374 3,441 3,562 3,892 4,041 4,441 
60–64 1,953 2,102 2,324 2,395 2,600 2,802 2,964 3,135 
65–69 1,347 1,397 1,478 1,501 1,680 1,814 2,018 2,220 
70+ 1,533 1,523 1,728 1,817 1,915 2,057 2,154 2,300 
All ages 76,972 75,423 76,612 75,904 75,611 79,026 81,740 85,636 
Ages 20–69 72,519 71,601 72,792 72,394 72,234 75,589 78,329 82,158 
Source: AIHW analysis of state and territory cervical screening register data.  
Table A4.2: Proportion of histology tests, by age, 2013  
Age group <20 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70+ 
Crude rate 1.4 10.8 16.5 13.7 11.5 12.4 11.3 8.3 5.2 3.7 2.6 2.7 
Note: ‘Crude rate’ is the number of histology tests as a proportion of the total number of histology tests. 
Source: AIHW analysis of state and territory cervical screening register data. 
Table A4.3: Histology tests as a proportion of cytology tests, by age, 2013  
Age group <20 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70+ 
Crude rate 2.3 4.7 5.5 4.3 3.8 3.9 4.0 3.1 2.4 2.1 2.0 7.4 
Note: ‘Crude rate’ is the number of histology tests as a proportion of the number of cytology tests. 
Source: AIHW analysis of state and territory cervical screening register data. 
Table A4.4: Negative histology tests, by age, 2013  
Age 
group 
<20 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70+ 
Number 331 2,458 3,719 3,743 4,449 6,442 6,850 5,369 3,391 2,404 1,714 1,858 
Crude 
rate 28.1 26.6 26.4 31.8 45.0 60.6 70.9 75.6 76.4 76.7 77.2 80.8 
Note: ‘Crude rate’ is the number of negative histology tests as a proportion of the total number of histology tests.  
Source: AIHW analysis of state and territory cervical screening register data. 
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Table A4.5: Abnormalities detected by histology in women aged 20–69, 2006 to 2013 
 2006 2007 2008 2009 2010 2011 2012 2013 
Low-grade abnormalities       
Number 18,003 16,602 15,347 14,576 14,018 14,566 14,856 15,318 
Crude rate 24.8 23.2 21.1 20.1 19.4 19.3 19.0 18.6 
AS rate 21.4 20.2 18.4 17.6 17.2 17.4 17.2 17.1 
High-grade abnormalities       
Number 20,063 21,067 22,102 22,031 22,104 22,676 23,149 23,734 
Crude rate 27.7 29.4 30.4 30.4 30.6 30.0 29.6 28.9 
AS rate 22.9 24.4 25.2 25.4 25.9 25.9 25.7 25.4 
All abnormalities (low-grade, high-grade and cancer)   
Number 38,825 38,476 38,325 37,380 36,940  38,122  38,984  40,038 
Crude rate 53.5 53.7 52.7 51.6 51.1 50.4 49.8 48.7 
AS rate 45.8 46.2 45.1 44.4 44.4 44.6 44.4 44.0 
Notes 
1. ‘Low-grade abnormalities’ are histology test results HS02 and HE02; ‘high-grade abnormalities’ are histology results HS03 and HE03. 
All abnormalities are histology test results HS02, HS03, HS04, HE02, HE03 and HE04 (see Table 3.2).  
2. Crude rate is the number of low-grade, high-grade, or all abnormalities detected by histology as a proportion of the total number of 
histology tests; ‘age-standardised (AS) rate’ is the number of low-grade, high-grade, or all abnormalities detected by histology as a  
proportion of the total number of histology tests age-standardised to the Australian population at 30 June 2001. 
3. This is the number of abnormalities detected, not the number of abnormal histology tests—in a small proportion of histology tests there may 
be more than one abnormality detected, both of which will be counted. 
Source: AIHW analysis of state and territory cervical screening register data.  
Table A4.6: Low-grade abnormalities detected by histology, by age, 2013  
Age 
group 
<20 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70+ 
Number 454 2,860 3,392 2,655 1,945 1,661 1,265 752 397 265 126 70 
Crude 
rate 38.6 31.0 24.1 22.6 19.7 15.6 13.1 10.6 8.9 8.5 5.7 3.0 
Note: ‘Crude rate’ is the number low-grade abnormalities detected by histology as a proportion of the total number of histology tests. 
Source: AIHW analysis of state and territory cervical screening register data. 
Table A4.7: High-grade abnormalities detected by histology, by age, 2013  
Age 
group 
<20 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70+ 
Number 373 3,754 6,787 5,100 3,227 2,174 1,219 678 366 240 189 91 
Crude 
rate 31.7 40.7 48.1 43.4 32.6 20.4 12.6 9.5 8.2 7.7 8.5 4.0 
Note: ‘Crude rate’ is the number of high-grade abnormalities detected by histology as a proportion of the total number of histology tests. 
Source: AIHW analysis of state and territory cervical screening register data. 
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Table A4.8: High-grade abnormality detection rate, by age, 2006 to 2013  
 2006 2007 2008 2009 2010 2011 2012 2013 
<20 13.2 11.6 10.8 8.9 7.8 7.1 6.4 5.7 
20–24 19.9 18.9 21.3 19.9 19.7 17.4 15.8 15.0 
25–29 17.7 17.8 19.3 19.0 19.9 19.4 20.0 20.3 
30–34 11.6 11.5 12.7 12.8 13.6 14.0 13.8 14.5 
35–39 7.2 7.3 7.8 7.6 8.3 9.0 9.2 9.4 
40–44 4.7 4.7 4.8 4.7 4.9 5.5 6.0 6.3 
45–49 3.2 3.2 3.3 3.3 3.5 3.8 3.7 4.0 
50–54 1.9 1.9 2.0 1.9 2.1 2.2 2.4 2.4 
55–59 1.5 1.4 1.3 1.3 1.7 1.7 1.6 1.6 
60–64 1.2 1.2 1.3 1.2 1.2 1.4 1.5 1.4 
65–69 1.4 1.3 1.3 1.1 1.1 1.1 1.1 1.4 
70+ 2.8 2.4 2.6 2.6 3.4 2.7 2.8 2.6 
Ages 20–69   
Number 15,115 15,671 16,457 16,257 16,291 16,641 16,808 17,609 
Crude rate 7.8 7.8 8.4 8.1 8.4 8.4 8.3 8.5 
AS rate 7.8 7.7 8.3 8.1 8.5 8.4 8.4 8.5 
95% CI 7.6–7.9 7.5–7.8 8.2–8.5 8.0–8.2 8.3–8.6 8.3–8.6 8.2–8.5 8.4–8.7 
Note: ‘Crude rate’ is the number of women with a high-grade abnormality detected by histology per 1,000 women screened; ‘age-standardised 
(AS) rate’ is the number of women with a high-grade abnormality detected by histology per 1,000 women screened, age-standardised to the 
Australian population at 30 June 2001. 
Source: AIHW analysis of state and territory cervical screening register data.  
 
Confidence intervals 
Confidence intervals are only presented in this report where it has been deemed important 
to show the degree of error due to rare events in small populations, to avoid potential 
misinterpretation of data, and/or to present data consistent with other publications. This 
includes the high-grade abnormality detection rate, incidence of cervical cancer and 
mortality from cervical cancer. 
Where shown, 95% confidence intervals can be used to determine if a statistically significant 
difference exists between compared values: where the confidence intervals do not overlap, 
the difference between rates is greater than that which could be explained by chance and is 
regarded as statistically significant. Because overlapping confidence intervals do not imply 
that the difference between two rates is definitely due to chance, it can only be stated that 
no statistically significant differences were found, and not that no differences exist.  
Judgment should be exercised in deciding whether or not any differences shown are of 
clinical significance. 
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Table A4.9: High-grade abnormality detection rate in women aged 20–69, by state and territory, 
2013 
 NSW Vic Qld WA SA Tas ACT NT Australia 
Number 5,352 4,012 3,809 2,118 1,398 397 267 256 17,609 
Crude rate 8.1 7.3 9.3 9.6 9.4 9.1 7.5 12.2 8.5 
AS rate 8.3 7.5 9.2 9.1 9.8 9.7 7.1 10.5 8.5 
95% CI 8.1–8.6 7.3–7.8 9.0–9.5 8.7–9.5 9.3–10.3 8.8–10.6 6.2–8.0 9.0–12.1 8.4–8.7 
Note: ‘Age-standardised (AS) rate’ is the number of women with a high-grade abnormality detected by histology per 1,000 women screened,  
age-standardised to the Australian population at 30 June 2001. 
Source: AIHW analysis of state and territory cervical screening register data.  
Table A4.10: Squamous abnormalities detected by histology in women aged 20–69, by squamous 
category, 2006 to 2013 
Squamous category 
Year   
2006 2007 2008 2009 2010 2011 2012 2013 
HS02 Low-grade squamous abnormality 
Number 17,937 16,540 15,292 14,538 13,964 14,504 14,802 15,269 
Per 100 histology tests 24.7 23.1 21.0 20.0 19.3  19.2 18.9 18.6 
% of squamous abnormalities 47.3 44.1 41.1 39.9 38.9 39.2 39.2 39.3 
HS03 High-grade squamous abnormality 
Number 19,508 20,437 21,411 21,379 21,389 21,941 22,365 22,946 
Per 100 histology tests 26.9 28.5 29.4 29.5 29.6 29.0 28.6 27.9 
% of squamous abnormalities 51.5 54.5 57.5 58.7 59.6 59.3 59.2 59.0 
HS04 Squamous cell carcinoma 
Number 466 516 530 474 528 551 641 651 
Per 100 histology tests 0.6 0.7 0.7 0.7 0.7 0.7 0.8 0.8 
% of squamous abnormalities 1.2 1.4 1.4 1.3 1.5 1.5 1.7 1.7 
All squamous abnormalities 
Number 37,911 37,493 37,233 36,391 35,881 36,996 37,808 38,866 
Crude rate 52.3 52.4 51.1 50.3 49.7 48.9 48.3 47.3 
AS rate 44.5 44.7 43.5 43.0 43.0 43.1 42.9 42.6 
Notes 
1. ‘HS03 High-grade squamous abnormality’ combines cervical intraepithelial neoplasia (CIN) not otherwise specified (NOS), CIN II and 
CIN III. 
2. ‘Crude rate’ is the number of each squamous abnormality or all squamous abnormalities combined detected by histology as a proportion of 
the total number of histology tests; ‘age-standardised (AS) rate’ is the number of all squamous abnormalities combined detected by 
histology as a proportion of the total number of histology tests age-standardised to the Australian population at 30 June 2001. 
Source: AIHW analysis of state and territory cervical screening register data.  
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Table A4.11: CIN II and CIN III in women aged 20–69, 2006 to 2013 
Squamous category 
Year  
2006 2007 2008 2009 2010 2011 2012 2013 
HS03.2 CIN II   
Number 3,909 4,104 4,377 4,574 4,338 4,157 4,236 4,293 
Per 100 histology tests (crude rate) 11.5 12.1 12.5 12.7 12.2 11.2 10.8 10.5 
Per 100 histology tests (AS rate) 9.5 9.8 10.2 10.4 10.1 9.6 9.5 9.3 
% of squamous abnormalities 24.7 25.5 25.9 26.7 26.6 25.5 25.0 24.9 
HS03.3 CIN III   
Number 4,350 4,753 5,340 5,373 5,127 5,293 5,868 5,896 
Per 100 histology tests (crude rate) 12.8 14.0 15.3 14.9 14.4 14.2 15.0 14.4 
Per 100 histology tests (AS rate) 11.1 12.0 13.0 12.6 12.4 12.4 13.2 12.8 
% of squamous abnormalities 27.5 29.6 31.6 31.3 31.5 32.4 34.7 34.2 
Source: AIHW analysis of state and territory cervical screening register data.  
Table A4.12: CIN II and CIN III, by age, 2013  
Age 
group 
<20 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70+ 
CIN II             
Number 103 869 1,244 789 502 429 220 131 44 40 25 9 
Crude 
rate 20.6 19.4 18.0 14.0 10.8 7.9 4.4 3.5 1.9 2.6 2.2 0.7 
CIN III             
Number 45 749 1,752 1,396 798 521 289 174 114 53 50 20 
Crude 
rate 9.0 16.7 25.4 24.7 17.1 9.6 5.8 4.6 4.9 3.4 4.3 1.7 
Note: ‘Crude rate’ is the number of high-grade abnormalities detected by histology as a proportion of the total number of histology tests. 
Source: AIHW analysis of state and territory cervical screening register data. 
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Table A4.13: Endocervical abnormalities detected by histology in women aged 20–69, by 
endocervical category, 2006 to 2013 
Endocervical category 
Year   
2006 2007 2008 2009 2010 2011 2012 2013 
HE02 Endocervical atypia   
Number 66 62 55 38 54 62 54 49 
% of cytology tests 0.09 0.09 0.08 0.05 0.07 0.08 0.07 0.06 
% of endocervical abnormalities 7.2 6.3 5.0 3.8 5.1 5.5 4.6 4.2 
HE03 High-grade endocervical abnormality   
Number 555 630 691 652 715 735 784 788 
% of cytology tests 0.77 0.88 0.95 0.90 0.99 0.97 1.00 0.96 
% of endocervical abnormalities 60.7 64.1 63.3 65.9 67.5 65.3 66.7 67.2 
HE04.1 & 4.2 Adenocarcinoma         
Number 257 245 311 263 248 283 284 275 
% of cytology tests 0.35 0.34 0.43 0.36 0.34 0.37 0.36 0.33 
% of endocervical abnormalities 28.1 24.9 28.5 26.6 23.4 25.1 24.1 23.5 
HE04.3 Adenosquamous carcinoma    
Number 15 25 21 20 21 33 23 32 
% of cytology tests 0.02 0.03 0.03 0.03 0.03 0.04 0.03 0.04 
% of endocervical abnormalities 1.6 2.5 1.9 2.0 2.0 2.9 2.0 2.8 
HE04.4 Carcinoma of the cervix (other)   
Number 21 21 14 16 21 13 31 28 
% of cytology tests 0.03 0.03 0.02 0.02 0.03 0.02 0.04 0.03 
% of endocervical abnormalities 2.3 2.1 1.3 1.6 2.0 1.2 2.6 2.4 
All endocervical abnormalities   
Number 914 983 1,092 989 1,059 1,126 1,176 1,172 
Crude rate 1.26 1.37 1.50 1.37 1.47 1.49 1.50 1.43 
AS rate 1.35 1.46 1.59 1.41 1.50 1.48 1.48 1.41 
Notes 
1. ‘HE03 High-grade endocervical abnormality’ combines endocervical dysplasia and adenocarcinoma in situ.  
2. ‘Crude rate’ is the number of each endocervical abnormality or of all endocervical abnormalities combined detected by histology as a 
proportion of the total number of histology tests; ‘age-standardised (AS) rate’ is the number of all endocervical abnormalities combined 
detected by histology as a proportion of the total number of histology tests age-standardised to the Australian population at 30 June 2001. 
Source: AIHW analysis of state and territory cervical screening register data.  
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A.5 Cytology-histology correlation 
Table A5.1: Number of squamous abnormalities detected by cytology in 2012, and proportion 
followed by squamous histology within 6 months, for women aged 20–69 
Cytology prediction 
Number detected by 
cytology 
Number followed  
by squamous histology 
Proportion followed  
by squamous histology (%) 
S2 Possible low-grade 52,007 8,427 16.2 
S3 Low-grade 36,047 8,105 22.5 
S4 Possible high-grade 12,848 9,504 74.0 
S5 High-grade 15,863 13,506 85.1 
S6 High-grade plus 346 305 88.2 
S7 Squamous cell carcinoma 153 129 84.3 
Source: AIHW analysis of state and territory cervical screening register data.  
Table A5.2: Correlation between squamous cytology and the most serious squamous histology 
within 6 months in women aged 20–69, cytology tests performed in 2012 
  Histology finding  
Cytology prediction 
HS02  
Low-grade 
HS03  
High-grade 
HS04  
squamous cell  
carcinoma 
S1 Negative 3,374  (16.9%) 930     (4.7%) 27    (0.1%) 
S2 Possible low-grade 3,475  (41.2%) 1,272  (15.1%) 10    (0.1%) 
S3 Low-grade 4,203  (51.9%) 1,632  (20.1%) 3    (0.0%) 
S4 Possible high-grade 2,304  (24.2%) 4,935  (51.9%) 51    (0.5%) 
S5 High-grade 1,654  (12.2%) 10,434  (77.3%) 214    (1.6%) 
S6 High-grade plus 10    (3.3%) 213  (69.8%) 69  (22.6%) 
S7 Squamous cell carcinoma 3    (2.3%) 31  (24.0%) 87  (67.4%) 
Notes 
1. Numbers and percentage of each squamous cytology result category are shown. 
2. For national consistency, the histology results of cervical intraepithelial (CIN) not otherwise specified (NOS), CIN II and CIN III are grouped 
together to form a broad high-grade abnormality category, and those of microinvasive and invasive squamous cell carcinoma are grouped 
together to form a broad squamous cell carcinoma category.  
Source: AIHW analysis of state and territory cervical screening register data.  
Table A5.3: Positive predictive value (PPV) of high-grade squamous cytological abnormalities in 
women aged 20–69, most serious histology within 6 months of cytology performed in 2008 to 2012 
 Cytology prediction 
 Possible high-grade S4 High-grade S5 High-grade plus S6 High-grade 
2008 53.8% (4,415/8,212) 78.4% (11,111/14,165) 92.2% (237/257)  69.6% (15,763/22,634) 
2009 55.2% (4,748/8,607) 78.9% (10,935/13,859) 90.5% (228/252) 70.0% (15,911/22,718) 
2010 54.8% (4,810/8,782) 79.2% (10,517/13,279) 92.4% (255/276) 69.8% (15,582/22,337)  
2011 51.6% (4,999/9,688) 79.3% (11,129/14,033) 90.3% (250/277) 68.2% (16,378/23,998) 
2012 52.5% (4,986/9,504) 78.8% (10,648/13,506) 92.5% (282/305) 68.3% (15,916/23,315) 
Note: The positive predictive value is calculated as the proportion of squamous cytology results of possible or definite high-grade abnormality that 
were confirmed on histology to be a high-grade squamous abnormality or squamous cell carcinoma.  
Source: AIHW analysis of state and territory cervical screening register data.  
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Table A5.4: Number of endocervical abnormalities detected by cytology in 2012, and proportion 
followed by endocervical histology within 6 months, for women aged 20–69 
Cytology prediction 
Number detected 
by cytology 
Number followed  
by histology 
Proportion followed  
by histology (%) 
E2 Atypical endocervical cells of uncertain significance 791 227 28.7 
E3 Possible high-grade 531 255 48.0 
E4 Adenocarcinoma in situ 266 240 90.2 
E5 Adenocarcinoma in situ plus 21 13 61.9 
E6 Adenocarcinoma 80 44 55.0 
Source: AIHW analysis of state and territory cervical screening register data.  
Table A5.5: Correlation between endocervical cytology and the most serious endocervical histology 
within 6 months, for women aged 20–69, cytology tests performed in 2012 
 Histology finding 
Cytology prediction 
HE02  
Endocervical atypia 
HE03  
High-grade 
HE04.1&4.2  
Adenocarcinoma 
E1 Negative 17  (0.1%) 330    (1.5%) 87    (0.4%) 
E2 Atypical endocervical cells of uncertain significance 3  (1.3%) 55  (24.2%) 14    (6.2%) 
E3 Possible high-grade 3  (1.2%) 114  (44.7%) 29  (11.4%) 
E4 Adenocarcinoma in situ 0  (0.0%) 152  (63.3%) 64  (26.7%) 
E5 Adenocarcinoma in situ plus 0  (0.0%) 6  (46.2%) 6  (46.2%) 
E6 Adenocarcinoma 0  (0.0%) 5  (11.4%) 29  (65.9%) 
Notes 
1. Numbers and percentage of each endocervical cytology result category shown. 
2. For national consistency, the histology results of endocervical dysplasia and adenocarcinoma in situ are grouped together to form a broad 
high-grade abnormality category, and microinvasive and invasive adenocarcinoma are grouped to form a broad adenocarcinoma category.  
3. The histology results of adenosquamous carcinoma and carcinoma of the cervix (other) are excluded, since these are neither solely 
squamous or endocervical in origin, and thus would not necessarily be expected to correlate with cytology results of either cell type.  
Source: AIHW analysis of state and territory cervical screening register data.  
Table A5.6: Positive predictive value (PPV) of high-grade endocervical cytological abnormalities in 
women aged 20–69, most serious histology within 6 months of cytology performed in 2008 to 2012 
 Cytology prediction 
 Possible  
high-grade E3 
Adenocarcinoma  
in situ E4 
Adenocarcinoma  
in situ plus E5 High-grade 
2008 49.3% (109/221) 92.2% (202/219) 96.0% (24/25) 72.0% (335/465) 
2009 54.1% (139/257) 89.2% (214/240) 78.6% (11/14) 71.2% (364/511) 
2010 56.3% (120/213) 88.7% (212/239) 73.9% (17/23) 73.5% (349/475) 
2011 55.6% (154/277) 86.0% (228/265) 100.0% (17/17) 71.4% (399/559) 
2012 56.1% (143/255) 90.0% (216/240) 92.3% (12/13) 73.0% (371/508) 
Note: The positive predictive value is calculated as the proportion of endocervical cytology results of possible or definite high-grade that were 
confirmed on histology to be a high-grade endocervical abnormality or adenocarcinoma. (These are prone to variability due to small numbers.)  
Source: AIHW analysis of state and territory cervical screening register data.  
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Table A5.7: Cytology prediction preceding a histology finding of adenosquamous carcinoma or 
other carcinoma of the cervix in women aged 20–69, cytology performed in 2012 
Cytology prediction  Adenosquamous carcinoma Carcinoma of the cervix (other) 
S1 Negative 2 13 
S2 Possible low-grade 0 1 
S3 Low-grade 0 0 
S4 Possible high-grade 0 2 
S5 High-grade 5 3 
S6 High-grade with possible invasion 2 1 
S7 Squamous cell carcinoma 2 4 
E1 Negative 7 18 
E2 Atypical endocervical cells of uncertain significance 0 0 
E3 Possible high-grade 1 0 
E4 Adenocarcinoma in situ 1 0 
E5 Adenocarcinoma with possible invasion 0 0 
E6 Adenocarcinoma 2 2 
Source: AIHW analysis of state and territory cervical screening register data.  
Table A5.8: Correlation between squamous cytology and the most serious squamous histology 
within 6 months in women aged 20–69 showing CIN II and CIN III, cytology tests performed in 
2012 
 Histology finding 
Cytology prediction 
HS02  
Low-grade 
HS03.2  
CIN II 
HS03.3  
CIN III 
HS04  
Squamous cell  
carcinoma 
S1 Negative 1,389   (15.1%) 238    (2.6%) 198    (2.1%) 5    (0.1%) 
S2 Possible low-grade 1,886   (37.0%) 423    (8.3%) 280    (5.5%) 4    (0.1%) 
S3 Low-grade 1,990   (48.9%) 481  (11.8%) 266    (6.5%) 1    (0.0%) 
S4 Possible high-grade 1,124   (21.4%) 1,055  (20.1%) 1,556  (29.7%) 26    (0.5%) 
S5 High-grade 759   (10.8%) 1,490  (21.3%) 3,886  (55.5%) 112    (1.6%) 
S6 High-grade plus  6    (3.9%) 9    (5.9%) 92  (60.5%) 40  (26.3%) 
S7 Squamous cell carcinoma 0    (0.0%) 1    (1.6%) 12  (19.7%) 44  (72.1%) 
Notes 
1. Numbers and percentage of each squamous cytology result category shown. 
2. States and territories unable to distinguish between CIN II and CIN III were excluded from all data and calculations in this table. 
3. The high-grade category CIN NOS has been excluded from this table, but is a rare histology finding. 
Source: AIHW analysis of state and territory cervical screening register data.  
 
  
  Cervical screening in Australia 2012–2013 53 
A.6 Incidence of cervical cancer 
Table A6.1: Incidence of cervical cancer, 1982 to 2011 
 New cases  AS rate 
Year of diagnosis 20–69 All ages  20–69 All ages 
1982 826 963  19.0 14.2 
1983 842 995  19.1 14.4 
1984 839 1,012  18.5 14.2 
1985 898 1,060  19.6 14.7 
1986 863 1,023  18.7 14.0 
1987 905 1,099  18.7 14.4 
1988 901 1,066  18.1 13.6 
1989 910 1,074  18.1 13.5 
1990 918 1,088  18.0 13.5 
1991 896 1,095  17.2 13.3 
1992 848 1,026  16.0 12.2 
1993 848 1,016  15.9 12.0 
1994 937 1,144  17.1 13.1 
1995 777 962  13.9 10.8 
1996 760 940  13.5 10.4 
1997 658 810  11.5 8.8 
1998 700 872  11.9 9.2 
1999 661 800  11.1 8.4 
2000 599 769  9.9 7.9 
2001 589 743  9.6 7.5 
2002 558 690  9.0 6.8 
2003 580 731  9.2 7.1 
2004 584 727  9.1 7.0 
2005 605 736  9.3 7.0 
2006 588 719  8.9 6.7 
2007 622 749  9.3 6.9 
2008 642 783  9.4 7.1 
2009 625 754  9.0 6.7 
2010 688 824  9.6 7.2 
2011 682 801  9.5 6.9 
Note: ‘Age-standardised (AS) rate’ is the number of new cases of cervical cancer per 100,000 women, age-standardised to the Australian 
population at 30 June 2001. 
Source: AIHW Australian Cancer Database 2011. 
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Table A6.2: Incidence of carcinoma of the cervix (squamous cell carcinoma, adenocarcinoma, 
adenosquamous carcinoma and other carcinoma) in women aged 20–69, 1982 to 2011 
 New cases  AS rate 
Year of 
diagnosis SCC(a) AC(b) ASC(c) Other(d) 
 
SCC(a) AC(b) ASC(c) Other(d) 
1982 656 92 22 35  15.1 2.1 0.5 0.8 
1983 662 83 23 56  15.1 1.9 0.5 1.2 
1984 634 87 45 51  13.9 1.9 1.0 1.1 
1985 689 95 35 55  15.1 2.0 0.8 1.1 
1986 646 117 42 40  13.9 2.5 1.0 0.8 
1987 681 132 41 33  14.0 2.7 0.9 0.7 
1988 650 157 40 41  13.1 3.1 0.8 0.8 
1989 692 111 50 48  13.8 2.2 1.0 1.0 
1990 643 146 49 61  12.6 2.8 1.0 1.2 
1991 646 144 41 56  12.4 2.8 0.8 1.1 
1992 612 137 50 37  11.5 2.6 1.0 0.7 
1993 595 143 48 52  11.2 2.6 0.9 1.0 
1994 639 203 40 49  11.7 3.7 0.7 0.9 
1995 546 146 34 41  9.8 2.6 0.6 0.7 
1996 529 148 40 33  9.4 2.6 0.7 0.6 
1997 454 130 33 31  7.9 2.3 0.6 0.5 
1998 492 141 30 29  8.4 2.4 0.5 0.5 
1999 470 132 24 27  7.9 2.2 0.4 0.5 
2000 401 118 30 28  6.7 2.0 0.5 0.5 
2001 400 115 32 28  6.5 1.9 0.5 0.5 
2002 388 126 17 20  6.2 2.0 0.3 0.3 
2003 396 122 25 26  6.3 1.9 0.4 0.4 
2004 391 133 27 22  6.1 2.1 0.4 0.3 
2005 399 128 21 39  6.2 2.0 0.3 0.6 
2006 365 143 22 38  5.6 2.2 0.3 0.6 
2007 393 158 24 37  5.9 2.3 0.4 0.6 
2008 418 166 21 25  6.1 2.4 0.3 0.4 
2009 406 162 23 19  5.9 2.3 0.3 0.3 
2010 450 148 30 40  6.3 2.1 0.4 0.5 
2011 457 165 26 22  6.4 2.3 0.4 0.3 
(a) SCC = squamous cell carcinoma. 
(b) AC = adenocarcinoma. 
(c) ASC = adenosquamous carcinoma. 
(d) Other = other and unspecified carcinoma. 
Note: ‘Age-standardised (AS) rate’ is the number of new cases of squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma and 
other carcinomas per 100,000 women age-standardised to the Australian population at 30 June 2001; rates based on fewer than 20 new cases 
should be interpreted with caution. 
Source: AIHW Australian Cancer Database 2011. 
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Table A6.3: Incidence of cervical cancer, by age, 2011 
 Age group (years) 
 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 
New cases 12 66 91 89 85 94 71 68 58 48 
Crude rate 1.5 8.1 11.8 11.3 10.6 12.0 9.4 10.1 9.4 10.0 
Note: ‘Crude rate’ is the number of new cases of cervical cancer per 100,000 women; rates based on fewer than 20 new cases should be 
interpreted with caution. 
Source: AIHW Australian Cancer Database 2011. 
Table A6.4: Incidence of cervical cancer in women aged 20–69, by state and territory, 2005–2009 
 NSW Vic  Qld WA SA Tas ACT NT Australia  
New cases 976 683 707 344 209 73 40 50 3,082 
AS rate 8.8 8.1 10.7 10.3 8.4 9.2 7.1 15.3 9.2 
95% CI 8.3–9.4 7.5–8.8 10.0–11.6 9.2–11.4 7.3–9.6 7.2–11.6 5.1–9.7 11.2–20.3 8.9–9.5 
Note: ‘Age-standardised (AS) rate’ is the number of new cases of cervical cancer per 100,000 women age-standardised to the Australian 
population at 30 June 2001. 95% CI are 95% confidence intervals. 
Source: AIHW Australian Cancer Database 2011. 
Table A6.5: Incidence of cervical cancer in women aged 20–69, by remoteness area, 2005–2009 
Remoteness 
area Major cities 
Inner and outer 
 regional 
Remote and  
very remote Australia 
New cases 2,127 852 92 3,082 
Rate 9.0 9.3 12.7 9.2 
95% CI 8.6–9.4 8.7–10.0 10.2–15.6 8.9–9.5 
Notes 
1. Women were allocated to a remoteness area using residential statistical local area (SLA) according to the 2006 Australian Standard 
Geographic Classifications. 
2. ‘Age-standardised (AS) rate’ is the number of new cases of cervical cancers per 100,000 women age-standardised to the Australian 
population at 30 June 2001. 95% CI are 95% confidence intervals. 
Source: AIHW Australian Cancer Database 2011. 
Table A6.6: Incidence of cervical cancer in women aged 20–69, by socioeconomic status, 2006–2009 
Socioeconomic 
status 
1 
(lowest)  
2 3 4 5  
(highest) Australia  
New cases 531 530 469 517 420 2,467 
Rate 10.2 9.9 8.7 9.5 7.4 9.1 
95% CI 9.3–11.1 9.1–10.8 7.9–9.5 8.7–10.4 6.7–8.2 8.8–9.5 
Notes 
1. Women were allocated to a socioeconomic status using residential SLA according to the Australian Bureau of Statistics Socio-Economic 
Indexes for Areas (SEIFA) Index of Relative Socio-Economic Disadvantage for 2006. 
2. ‘Age-standardised (AS) rate’ is the number of new cases of cervical cancers per 100,000 women age-standardised to the Australian 
population at 30 June 2001. 95% CI are 95% confidence intervals. 
3. Australian total may not equal sum of the quintiles due to estimation of SES status variable.  
Source: AIHW Australian Cancer Database 2011. 
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Table A6.7: Incidence of cervical cancer in women aged 20–69 (New South Wales, Queensland, 
Western Australia, and Northern Territory), by Indigenous status, 2005–2009 
  New South Wales, Queensland, Western Australia, and the Northern Territory(a) 
 Aboriginal and Torres Strait 
Islander Non-Indigenous Total(b) 
New cases 114 1,802 2,077 
Crude rate 17.4 8.7 9.7 
AS rate 19.5 8.7 9.8 
95% CI 15.9–23.6 8.3–9.1 9.3–10.2 
(a)  Data shown for ‘Aboriginal and Torres Strait Islander’, ‘Non-Indigenous’ and ‘Total’ are for New South Wales, Queensland, Western 
Australia and the Northern Territory only; data from these jurisdictions were considered to have adequate levels of Indigenous identification 
in cancer registration data at the time this report was prepared.  
(b) Total includes those whose Indigenous status is not stated.  
Notes 
1. ‘Crude rate’ is the number of new cases of cervical cancer per 100,000 women; ‘age-standardised (AS) rates’ are the number of cervical 
cancers detected per 100,000 women directly age-standardised to the Australian population at 30 June 2001. 95% CI are 95% confidence 
intervals. 
2. Some states and territories use an imputation method for determining Indigenous cancers, which may lead to differences between these 
data and those shown in jurisdictional cancer incidence reports. 
Source: AIHW Australian Cancer Database 2011. 
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A.7 Mortality from cervical cancer 
Table A7.1: Mortality from cervical cancer, 1982–2012 
 Deaths  AS rate 
Year 20–69 All ages  20–69 All ages 
1982 237 346  5.5 5.2 
1983 248 343  5.6 5.0 
1984 223 339  5.0 4.9 
1985 234 363  5.1 5.1 
1986 240 341  5.1 4.6 
1987 225 348  4.8 4.6 
1988 219 345  4.5 4.5 
1989 243 369  4.9 4.7 
1990 245 339  4.8 4.2 
1991 204 331  4.0 4.0 
1992 188 322  3.6 3.8 
1993 204 318  3.9 3.7 
1994 223 341  4.2 4.0 
1995 211 334  3.9 3.8 
1996 174 301  3.1 3.3 
1997 160 285  2.8 3.0 
1998 153 260  2.6 2.7 
1999 131 227  2.2 2.3 
2000 154 265  2.6 2.6 
2001 156 271  2.5 2.6 
2002 126 217  2.0 2.1 
2003 140 239  2.2 2.2 
2004 119 210  1.8 1.9 
2005 136 221  2.0 2.0 
2006 137 228  2.0 2.0 
2007 125 201  1.8 1.7 
2008 145 237  2.0 2.0 
2009 144 242  1.9 1.9 
2010 150 229  2.0 1.9 
2011 152 228  2.0 1.8 
2012 143 226  1.8 1.8 
Notes  
1. Deaths from 1982 to 2011 were derived by year of death; deaths in 2012 were derived by year of registration of death. Deaths registered in 
2010 and earlier are based on the final version of cause-of-death data; deaths registered in 2011 and 2012 are based on revised and 
preliminary versions, respectively, and are subject to further revision by the ABS. 
2. ‘Age-standardised (AS) rate’ is number of deaths from cervical cancer per 100,000 women age-standardised to the Australian population at 
30 June 2001. 
Source: AIHW National Mortality Database. 
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Table A7.2: Mortality from cervical cancer, by age, 2012 
 Age group (years) 
 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 
Deaths 0 3 7 17 13 10 23 24 28 18 
Crude rate 0.0 0.4 0.9 2.2 1.6 1.3 3.0 3.5 4.5 3.5 
Notes 
1. Deaths in 2012 were derived using year of registration. Deaths registered in 2012 are based on the preliminary version of cause-of-death 
data and are subject to further revision by the ABS. 
2. ‘Crude rate’ is the number of deaths from cervical cancer per 100,000 women; age-specific rates based on less than 20 deaths should be 
interpreted with caution. 
Source: AIHW National Mortality Database. 
Table A7.3: Mortality from cervical cancer in women aged 20–69, by state and territory, 2008–2012 
 NSW Vic  Qld WA SA Tas ACT NT Australia  
Deaths 254 154 165 74 51 19 7 10 734 
AS rate 2.1 1.7 2.2 2.0 1.9 2.1 1.2 3.0 2.0 
95% CI 1.8–2.4 1.4–1.9 1.9–2.5 1.5–2.5 1.4–2.5 1.2–3.3 0.5–2.5 1.4–5.6 1.8–2.1 
Notes 
1. Deaths from 2008 to 2011 were derived by year of death; deaths in 2012 were derived by year of registration of death. Deaths registered in 
2010 and earlier are based on the final version of cause-of-death data; deaths registered in 2011 and 2012 are based on revised and 
preliminary versions, respectively, and are subject to further revision by the ABS.  
2. ‘Age-standardised (AS) rate’ is the number of deaths from cervical cancer per 100,000 women, age-standardised to the Australian 
population at 30 June 2001; rates based on less than 20 deaths should be interpreted with caution. 95% CI are 95% confidence intervals. 
Source: AIHW National Mortality Database. 
Table A7.4: Mortality from cervical cancer in women aged 20–69, by remoteness area, 2008–2012 
Remoteness  
area Major cities 
Inner and outer 
regional 
Remote and  
very remote Australia 
Deaths 467 238 25 734 
AS rate 1.8 2.2 3.4 2.0 
95% CI 1.6–2.0 1.9–2.5 2.2–5.0 1.8–2.1 
Notes 
1. Women were allocated to a remoteness area using residential statistical local area (SLA) according to the Australian Standard Geographic 
Classification for 2008–2010 and using residential statistical area level 2 (SA2) according to the Australian Statistical Geography Standard 
for 2011–2012. 
2. Deaths from 2008 to 2011 were derived by year of death; deaths in 2012 were derived by year of registration of death. Deaths registered in 
2010 and earlier are based on the final version of cause-of-death data; deaths registered in 2011 and 2012 are based on revised and 
preliminary versions, respectively, and are subject to further revision by the ABS. 
3. ‘Age-standardised (AS) rate’ is the number of deaths from cervical cancers per 100,000 women age-standardised to the Australian 
population at 30 June 2001. 95% CI are 95% confidence intervals. 
Source: AIHW National Mortality Database. 
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Table A7.5: Mortality from cervical cancer in women aged 20–69 (New South Wales, Queensland, 
Western Australia, South Australia and Northern Territory), by Indigenous status, 2008–2012 
 New South Wales, Queensland, Western Australia, South Australia and  
the Northern Territory(a) 
 Aboriginal and Torres Strait 
Islander Non-Indigenous Total(b) 
Deaths 47 497 554 
Crude rate 6.2 2.0 2.2 
AS rate 7.7 1.9 2.1 
95% CI 5.6–10.3 1.7–2.1 1.9–2.3 
(a)  Data shown for ‘Aboriginal and Torres Strait Islander’, ‘Non-Indigenous’ and ‘Total’ are for New South Wales, Queensland, Western 
Australia, South Australia and the Northern Territory only; data from these jurisdictions were considered to have adequate levels of 
Indigenous identification in cancer mortality data at the time this report was prepared.  
(b) Total includes those whose Indigenous status is not stated.  
Notes 
1. ‘Crude rate’ is the number of deaths from cervical cancer per 100,000 women; ‘age-standardised (AS) rate’ is the number of deaths from 
cervical cancer per 100,000 women directly age-standardised to the Australian population at 30 June 2001. 95% CI are 95% confidence 
intervals. 
2. Deaths from 2008 to 2011 were derived by year of death; deaths in 2012 were derived by year of registration of death. Deaths registered in 
2010 and earlier are based on the final version of cause-of-death data; deaths registered in 2011 and 2012 are based on revised and 
preliminary versions, respectively, and are subject to further revision by the ABS.  
Source: AIHW National Mortality Database. 
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Appendix B: National Cervical Screening 
Program information 
In 1991, the Australian Health Ministers’ Advisory Council (AHMAC) accepted 
recommendations made by the Screening Evaluation Steering Committee in the Australian 
Institute of Health report Cervical cancer screening in Australia: options for change (AIHW 1991) 
that saw the establishment of the Organised Approach to Preventing Cancer of the Cervix, 
Australia’s cervical screening program. Now known as the National Cervical Screening 
Program, it operates as a joint program of the Australian Government and state and territory 
governments, targeting women aged 20–69. A statement of the current national policy for 
cervical screening in Australia appears in the box below. 
Overview Box B1: National policy for Australia’s National Cervical Screening 
Program 
The national policy has been in place since 1991 and states:  
• Routine screening with Pap smears should be carried out every two years for women 
who have no symptoms or history suggestive of cervical cancer. 
• All women who have ever been sexually active should start having Pap smears 
between the ages of 18 and 20, or one or two years after first having sexual intercourse, 
whichever is later. 
• Pap smears may cease at the age of 70 for women who have had two normal Pap 
smears within the past five years. Women over 70 who have never had a Pap smear, or 
who request a Pap smear, should be screened. 
Women with abnormal smear results should be managed in accordance with the National 
Health and Medical Research Council’s guidelines. 
Source: Department of Health (Health 2015)  
The National Health and Research Council’s (NHMRC) Screening to prevent cervical cancer: 
guidelines for the management of asymptomatic women with screen detected abnormalities (NHMRC 
2005) provides recommendations for the management of women with an abnormal Pap test 
result. They enable practitioners and clinicians to manage the abnormalities detected by Pap 
tests according to evidence-based information which guides best practice. 
A cervical screening register or ‘Pap test register’ operates in every state and territory of 
Australia. Cervical screening registers fulfil many important roles, including sending 
reminder letters to women overdue for screening, providing a safety net for women who 
have not had follow-up of an abnormal result, and providing cytology laboratories and 
cervical cytology providers with previous results for a woman, to allow a more detailed 
evaluation of present findings. State and territory cervical cytology registries also provide 
data on the epidemiology and natural history of precancerous lesions, as well as providing 
data for national monitoring of the NCSP. These registers are key to the NCSP and were 
established along with the program in 1991. 
High-quality cervical cytology in Australian pathology laboratories has also been a key 
component of the screening program, facilitated through the development of National 
Pathology Accreditation Advisory Council (NPAAC) Performance measures for Australian 
laboratories reporting cervical cytology (NPAAC 2006). 
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Performance indicators 
The effectiveness of the NCSP has been monitored since 1996–1997 using performance 
indicators developed to monitor what were originally defined as essential aspects of the 
program. Full definitions of the original performance indicators can be found in Breast and 
cervical cancer screening in Australia 1996–1997 (AIHW 1998). New performance indicators 
were developed following a review that considered changes to both the NCSP and the 
cervical screening environment to ensure the NCSP continued to be monitored optimally. 
These new performance indicators were officially endorsed in September 2009 by the 
Screening Subcommittee of the Australian Population Health Development Principal 
Committee for use by the NCSP, and appeared for the first time in Cervical screening in 
Australia 2008–2009.  
The table below lists the current performance indicators for the NCSP. 
Table B1: Performance indicators for the National Cervical Screening Program 
Performance indicator Definition 
1  Participation The percentage of women aged 20–69 who have a 
Papanicolaou smear or ‘Pap test’ in a 2-year period 
2  Rescreening  
   2.1  Early rescreening The proportion of women who have another Pap test within  
21 months of a negative Pap test result  
   2.2  Rescreening after 27-month cervical screening  
   register reminder letter 
The proportion of women who have a Pap test within  
3 months of being sent a 27-month reminder letter 
3  Cytology The number of Pap test results in each result category  
4  Histology The number of histology results in each result category 
(including the number of women with a high-grade histology 
for every 1,000 women screened) 
5  Cytology-histology correlation A measure of how well cytology correlates with histology 
performed not more than 6 months after the cytology test 
6  Incidence The number of new cases of cervical cancer 
7  Mortality The number of deaths from cervical cancer 
Note: Further details and definitions of performance indicators are available in previous reports Cervical screening in Australia 2008–2009 to 
Cervical screening in Australia 2011-2012, and in the National cervical cancer prevention data dictionary version 1: working paper (AIHW 2014b). 
Source: National cervical cancer prevention data dictionary version 1: working paper (AIHW 2014b). 
Standards 
While there are no official standards for NCSP performance indicators, NPAAC standards in 
Performance measures for Australian laboratories reporting cervical cytology (NPAAC 2006) have 
been used in this report to provide a benchmark for the data presented. These are used as a 
guide to interpretation only, since this is a different purpose to that for which these 
standards were developed, and differences in definitions and data may exist. 
NPAAC Standards that relate to these data, along with data analysed by the AIHW, appear 
in Table 3.2 in this report. 
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Table B2: Contacts and links for the state and territory and Australian Government components of 
the National Cervical Screening Program 
NSW Cervical Screening Program 
Tel: (02) 8374 5757 
Fax: (02) 8374 5700 
Email: cervicalscreening@cancerinstitute.org.au 
<http://www.csp.nsw.gov.au/> 
 
PapScreen Victoria 
Tel: (03) 9635 5000 
Fax: (03) 9635 5360 
Email: papscreen@cancervic.org.au 
<http://www.papscreen.org.au> 
 
Qld Cervical Screening Program 
Tel: (07) 3328 9467 
Fax: (07) 3328 9487 
Email: cssb@health.gov.au 
<http://www.health.qld.gov.au/cervicalscreening/> 
 
WA Cervical Cancer Prevention Program 
Tel: (08) 9323 6788 
Fax: (08) 9323 6711 
Email: cervicalcancer@health.wa.gov.au 
<http://www.health.wa.gov.au/cervical/home/> 
 
SA Cervix Screening Program 
Tel: (08) 8226 8181 
Fax: (08) 8226 8190 
Email: cervixscreening@health.sa.gov.au 
<http://www.sahealth.sa.gov.au/wps/wcm/connect/Public+Con
tent/SA+Health+Internet/About+us/Department+of+Health/Pu
blic+Health+and+Clinical+Systems/Public+Health+Services/S
A+Cervix+Screening+Program/SA+Cervix+Screening+Progra
m> 
Tasmanian Cervical Cancer Prevention Program 
Tel: (03) 6216 4300 
Fax: (03) 6216 4309 
Email: canscreen@dhhs.tas.gov.au 
 
<http://www.dhhs.tas.gov.au/cancerscreening/TCSR> 
ACT Cervical Screening Program 
Tel: (02) 6205 1545 
Fax: (02) 6205 5035 
Email: pap.register@act.gov.au 
<http://www.health.act.gov.au/paptest> 
 
Cervical Screen NT 
Tel: (08) 8922 6444 
Fax: (08) 8922 6455 
Email: wcpp.ths@nt.gov.au 
<http://www.health.nt.gov.au/Womens_Health/Well_Womens_
Cancer_Screening/index.aspx> 
 
Australian Government Department of Health  
cancerscreening@health.gov.au 
 
<http://www.cancerscreening.gov.au/internet/screening/publis
hing.nsf/Content/cervical-screening-1> 
Australian Institute of Health and Welfare  
screening@aihw.gov.au <http://www.aihw.gov.au/cancer/screening/cervical/> 
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Appendix C: Data sources 
Data used in this report are derived from multiple sources and are summarised in Table C1 
below. 
Table C1: Data sources for Cervical screening in Australia 2012–2013 
Data used to monitor cervical screening in Australia Data source 
Monitoring cervical screening in Australia using NCSP data 
Performance Indicator 1 Participation State and territory cervical screening registers, ABS 
population data; AIHW National Hospital Morbidity Database 
Performance Indicator 2 Rescreening State and territory cervical screening registers 
Performance Indicator 3 Cytology State and territory cervical screening registers 
Performance Indicator 4 Histology State and territory cervical screening registers 
Performance Indicator 5 Cytology-histology correlation State and territory cervical screening registers 
Monitoring cervical screening in Australia using AIHW data 
Performance Indicator 6 Incidence of cervical cancer AIHW Australian Cancer Database 2011; ABS population 
data 
Performance Indicator 7 Mortality from cervical cancer AIHW National Mortality Database; ABS population data 
Monitoring other aspects of cervical screening in Australia 
Monitoring the safety of cervical screening management 
guidelines 
State and territory cervical screening registers 
Expenditure on cervical screening AIHW Health Expenditure Database; Medicare Australia 
Statistics 
State and territory cervical screening registers 
Data for the performance indicators participation, rescreening, cytology, histology and the 
cytology-histology correlation are provided by the cervical screening register in each state 
and territory according to definitions and data specifications in the National cervical cancer 
prevention data dictionary version 1 (AIHW 2014b). These data are compiled into national 
figures by the AIHW to allow national monitoring of the NCSP.  
The Data Quality Statement for cervical screening data appears in Appendix D, and can also 
be found on the AIHW website at 
<http://meteor.aihw.gov.au/content/index.phtml/itemId/569669>. 
AIHW Australian Cancer Database 
All forms of cancer, except basal and squamous cell carcinomas of the skin, are notifiable 
diseases in each Australian state and territory. This means there is legislation in each 
jurisdiction that requires hospitals, pathology laboratories and various other institutions to 
report all cases of cancer to their central cancer registry. An agreed subset of the data 
collected by these cancer registries is supplied annually to the AIHW, where they are 
compiled into the Australian Cancer Database (ACD). The ACD currently contains data on 
all cases of cancer diagnosed from 1982 to 2009 for all states and territories, and for 2010 and 
2011 for all except NSW and the ACT. 
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The 2010 and 2011 incidence data for NSW and the ACT were not available for inclusion in 
the 2011 version of the ACD. The development of the new NSW Cancer Registries system 
has resulted in a delay in processing incidence data for 2010 onwards and therefore the most 
recent NSW data available for inclusion in the ACD are for 2009. Full details about this 
situation are given at: <http://www.cancerinstitute.org.au/data-and-statistics/accessing-
our-data/availability-of-nsw-central-cancer-registry-data>. As the coding of ACT cancer 
notifications is contracted to the NSW Cancer Registry, the most recent data available for the 
ACT are also for 2009.  
The 2010 and 2011 incidence data for NSW and the ACT were estimated by the AIHW. These 
estimates were combined with the actual data supplied by the other 6 state and territory 
cancer registries to form the 2011 ACD. The detailed methodology by which data for NSW 
and the ACT were estimated for 2010 and 2011 is available in Appendix F of Cancer in 
Australia: an overview 2014 (AIHW 2014a). 
Cancer reporting and registration is a dynamic process, and records in the state and territory 
cancer registries may be modified if new information is received. As a result, the number of 
cancer cases reported by the AIHW for any particular year may change slightly over time 
and may not always align with state and territory reporting for that same year. 
Data have been analysed using the year of diagnosis of cancer. This is a more accurate 
reflection of incidence during a particular year than the year of registration of cancer. 
The Data Quality Statement for the ACD 2011 can be found on the AIHW website at 
<http://meteor.aihw.gov.au/content/index.phtml/itemId/586979>. 
AIHW National Mortality Database 
The AIHW National Mortality Database (NMD) contains information provided by the 
Registries of Births, Deaths and Marriages and the National Coronial Information System, 
and coded by the ABS, for deaths from 1964 to 2012. Registration of deaths is the 
responsibility of the state and territory registrars of births, deaths and marriages. These data 
are then collated and coded by the ABS and are maintained at the AIHW in the NMD. 
In the NMD, the year of occurrence of the death, and the year in which the death was 
registered, are both provided. For the purposes of this report, actual mortality data are 
shown based on the year of occurrence of the death, except for the most recent year (2012) 
where the number of people whose death was registered is used. Previous investigation has 
shown that the year of death and its registration coincide for the most part. However, in 
some instances, deaths at the end of each calendar year may not be registered until the 
following year. Thus, year-of-death information for the latest available year is generally an 
underestimate of the actual number of deaths that occurred in that year. 
In this report, deaths registered in 2010 and earlier are based on the final version of cause-of-
death data; deaths registered in 2011 and 2012 are based on revised and preliminary 
versions, respectively, and are subject to further revision by the ABS. 
A statement on data quality relating to the AIHW NMD is available at the following ABS 
website: Quality declaration summary, Causes of death, 2012, ABS cat. no. 3303.0 
<http://www.abs.gov.au/AUSSTATS/abs@.nsf/Latestproducts/3303.0Quality%20Declarat
ion02012?opendocument&tabname=Notes&prodno=3303.0&issue=2012&num=&view=>. 
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ABS Population data 
Throughout this report, population data were used to derive rates of participation in cervical 
screening, cervical cancer incidence and cervical cancer mortality. The population data were 
sourced from the ABS using the most up-to-date estimates available at the time of analysis. 
To derive their estimates of the resident populations, the ABS uses the 5-yearly Census of 
Population and Housing data and adjusts it as follows: 
• All respondents in the Census are placed in their state or territory, Statistical Local Area 
(SLA) and postcode of usual residence; overseas visitors are excluded. 
• An adjustment is made for persons missed in the Census. 
• Australians temporarily overseas on Census night are added to the usual residence 
Census count. 
Estimated resident populations are then updated each year from the Census data, using 
indicators of population change such as births, deaths and net migration. More information 
is available from the ABS website at <www.abs.gov.au>. 
For the Indigenous comparisons in this report, the most recently released Indigenous 
experimental estimated resident populations as released by the ABS were used. Those 
estimates were based on the 2011 Census of Population and Housing. 
ABS population data for participation calculations 
Participation rates were calculated using the average of the estimated resident female 
population for the 2-year, 3-year or 5-year reporting period. Denominators for participation 
rates were calculated using the average of the ABS estimated resident population for 2012 
and 2013 for 2-year participation; the average for 2011, 2012 and 2013 for 3-year 
participation; and the average of the ABS estimated resident population for 2009, 2010, 2011, 
2012 and 2013 for 5-year participation. These average populations were then adjusted for the 
estimated proportion of women who have had a hysterectomy using national hysterectomy 
fractions derived from the AIHW National Hospital Morbidity Database (NHMD). 
Note that there is the potential for variation in published participation rates between the 
AIHW and state and territory reports because of different sources of estimated resident 
population data, and/or different hysterectomy fractions used in calculations. 
Hysterectomy fractions 
Hysterectomy fractions represent the proportion of women with an intact uterus (and cervix) 
at a particular age, and are the tool used to adjust the population for participation 
calculations. This is because women who have had a hysterectomy with their cervix removed 
are not at risk of cervical cancer and thus do not require screening, and since substantial 
proportions (20–30%) of middle-aged and older women in Australia do not have an intact 
cervix, the population is adjusted to remove these women so that true participation in 
cervical screening can be more accurately estimated. 
Previously, the AIHW used hysterectomy fractions derived from self-reported information 
on hysterectomies collected in the 2001 National Health Survey (NHS) conducted by the 
ABS. However, hysterectomy incidence has fallen since 2001, which means the 2001 NHS 
hysterectomy fractions no longer allow accurate estimates. Thus the introduction of new 
performance indicators in the AIHW annual monitoring report, Cervical screening in Australia 
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2008–2009, provided an appropriate opportunity to update the method by which 
hysterectomy fractions were estimated.  
The National Hospital Morbidity Database (NHMD) is based on summary records of patient 
separations, referring to episodes of care in public and private hospitals, and allows us to 
view relatively complete hysterectomy numbers and rates for financial years from the mid-
1990s. These data were used, with projections forward and backward where required, to 
generate estimates of current hysterectomy prevalence for women aged 20–69. Published 
hysterectomy incidence trends, as well as data from the 1995, 2001 and 2004–05 NHS, were 
drawn on to ensure accuracy in assumptions.  
The results of these combined approaches are robust hysterectomy fractions that reflect both 
historical and current hysterectomy trends, which can be used in the calculation of 
participation in cervical screening for the most recent participation data. 
The fractions themselves are similar to previous estimates taken from population health 
surveys with the proportion of women with an intact cervix remaining comparatively higher 
in most age groups—a reflection of the national trend of decreasing incidence of 
hysterectomies over time. These are shown next to the previously adopted hysterectomy 
fractions based on the 2001 NHS in Table C2, below. 
Table C2: National hysterectomy fractions, 2011 
 % of women who have not had a hysterectomy 
Age group (years) Derived from NHS 2001 Modelled on NHMD 
20–24 100.0 100.0 
25–29 100.0 99.7 
30–34 98.9 98.8 
35–39 95.6 96.2 
40–44 90.6 91.6 
45–49 82.5 85.9 
50–54 76.5 81.0 
55–59 66.2 77.2 
60–64 68.9 73.6 
65–69 66.8 70.6 
Source: AIHW analysis of the National Hospital Morbidity Database.  
The incorporation of these new hysterectomy fractions, based on lower prevalence of 
hysterectomy procedures, into cervical screening participation calculations results in a slight 
decrease in the participation rate compared to calculations using the previous hysterectomy 
fractions—as would be expected, since the population at risk (and therefore the population 
eligible for cervical screening) is larger. 
ABS population data for incidence and mortality calculations 
Incidence and mortality rates were calculated using the estimated resident population for 
single-year calculations, and the aggregate of the estimated resident populations for the 5 
relevant years for 5-year calculations (or 4 years in the case of incidence for different groups 
of socioeconomic status). 
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AIHW National Hospital Morbidity Database 
The AIHW National Hospital Morbidity Database (NHMD) is compiled from data supplied 
by the state and territory health authorities. It is a collection of electronic confidentialised 
summary records for episodes of admitted patient care (separations or hospitalisations) in 
essentially all public and private hospitals in Australia. The data include demographic, 
administrative and clinical information, including patient diagnoses and other procedures. 
In this report, the NHMD is only used as the source of data for hysterectomy fractions, which 
are used to adjust ABS population data for the estimated proportion of women who have 
had a hysterectomy for participation calculations. 
The Data Quality Statement for the AIHW NHMD 2012–13 can be found at the AIHW 
website at <http://meteor.aihw.gov.au/content/index.phtml/itemId/568730>. 
AIHW Disease Expenditure Database 
The AIHW Disease Expenditure Database contains estimates of expenditure by disease 
category, age group and sex for each of the following areas of expenditure: admitted patient 
hospital services, out-of-hospital medical services, prescription pharmaceuticals, 
optometrical and dental services, community mental health services and public health cancer 
screening. 
For more information on the AIHW Disease Expenditure Database, see Health system 
expenditures on cancer and other neoplasms in Australia: 2008–09 (AIHW 2013a). 
The Data Quality Statement for the Disease Expenditure Database can be found on the 
AIHW website at <http://meteor.aihw.gov.au/content/index.phtml/itemId/512599>. 
Medicare Australia Statistics 
Medicare Australia Statistics is an online resource of the Department of Human Services, 
available at <http://medicarestatistics.humanservices.gov.au/statistics/mbs_item.jsp>. 
The resource was used to source Australian Government expenditure data for Medicare 
Benefit Scheme (MBS) items for cervical screening (including MBS items for cervical cytology 
tests and Practice Incentive Program (PIP) incentive payments). These expenditure data were 
then combined with expenditure data sourced from the AIHW Disease Expenditure 
Database to produce estimates of expenditure on cervical screening in Australia. 
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Appendix D: Data quality statement 
Data Quality Statement: Cervical screening data 
2012–2013 
Summary of key issues 
• All states and territories maintain population-based cervical screening registers (also 
referred to as ’Pap test registers’ or ‘Pap smear registers’) to which all cervical cytology, 
histology, and human papillomavirus (HPV) DNA tests are reported. 
• State and territory cervical screening registers were established to support the National 
Cervical Screening Program (NCSP) that commenced in 1991. 
• The AIHW compiles cervical screening data using aggregate data supplied from state 
and territory cervical screening registers in order to monitor the NCSP annually. 
• Some duplication may occur where the same test is reported to the cervical cytology data 
in 2 or more jurisdictions. AIHW is unable to identify or resolve these instances, and the 
level of duplication is unknown, but believed to be small. 
• Cervical screening register databases change every day, adding new records and 
improving the quality of existing records as new information becomes available. 
Description  
All states and territories have legislation that requires pathology laboratories to send all 
cervical tests to the relevant state or territory population-based cervical screening register. 
Cervical screening programs in each state and territory interrogate their own cervical 
screening register in accordance with detailed data specifications to supply aggregate data 
annually to the AIHW. These data are compiled into the only repository of national cervical 
screening data, although because these are aggregate and not unit record data, these data do 
not exist in a database per se, and cannot be interrogated further.  
Any Pap test performed in Australia, unless the woman has opted-off, will be included in 
NCSP data. This means that NCSP data is a virtually complete repository of all cervical 
screening performed in Australia. 
Institutional environment 
The Australian Institute of Health and Welfare (AIHW) is a major national agency set up by 
the Australian Government under the Australian Institute of Health and Welfare Act 1987 to 
provide reliable, regular and relevant information and statistics on Australia’s health and 
welfare. It is an independent corporate Commonwealth entity established in 1987, governed 
by a management Board, and accountable to the Australian Parliament through the Health 
portfolio. 
The AIHW aims to improve the health and wellbeing of Australians through better health 
and welfare information and statistics. It collects and reports information on a wide range of 
topics and issues, ranging from health and welfare expenditure, hospitals, disease and 
injury, and mental health, to ageing, homelessness, disability and child protection. 
The Institute also plays a role in developing and maintaining national metadata standards. 
This work contributes to improving the quality and consistency of national health and 
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welfare statistics. The Institute works closely with governments and non-government 
organisations to achieve greater adherence to these standards in administrative data 
collections to promote national consistency and comparability of data and reporting. 
One of the main functions of the AIHW is to work with the states and territories to improve 
the quality of administrative data and, where possible, to compile national datasets based on 
data from each jurisdiction, to analyse these datasets and disseminate information and 
statistics. 
The Australian Institute of Health and Welfare Act 1987, in conjunction with compliance to the 
Privacy Act 1988 (Cwth), ensures that the data collections managed by the AIHW are kept 
securely and under the strictest conditions with respect to privacy and confidentiality. 
For further information see the AIHW website <www.aihw.gov.au>. 
The AIHW has been receiving cervical screening data since 1989.  
Timeliness 
Cervical cytology data are available within about 6 months (there can be a lag of up to 6 
months in the transmission of test results from pathology laboratories to cervical screening 
registers), and data for the previous calendar year are supplied in July each year (rescreening 
and correlation data lag behind, as the specifications for these require a specified period of 
time to pass before this can be accurately calculated). 
The current cervical screening data are for cervical cytology and histology tests performed in 
2012 and 2013.  
Accessibility 
Cervical screening data are published annually in the report Cervical screening in Australia, 
available on the AIHW website <http://www.aihw.gov.au/cervical-cancer-screening/> 
where they can be downloaded without charge. Supplementary data tables that provide 
more detailed data are also provided to accompany each report, and these, too, are available 
on the AIHW website where they can be downloaded without charge. 
General enquiries about AIHW publications can be made to the Digital and Media 
Communications Unit on (02) 6244 1000 or via email to <info@aihw.gov.au>.  
Interpretability 
While many concepts in the report Cervical screening in Australia are easy to interpret, other 
concepts and statistical calculations are more complex and may be confusing to some users. 
All concepts are explained within the body of the report presenting these data, along with 
footnotes to provide further details and caveats. Appendix C provides additional detail on 
the data sources and classifications, and Appendix E provides details on the statistical 
methods used. 
Relevance 
Cervical screening data are highly relevant for monitoring trends in cervical screening 
participation and abnormality detection. The data are used for many purposes by policy-
makers and researchers, but are supplied and analysed specifically to monitor and inform 
the NCSP. 
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Accuracy 
All data provided by state and territory cervical screening programs, once analysed, are 
supplied back for verification. 
Further, National Pathology Accreditation Advisory Council (NPAAC) Performance measures 
for Australian laboratories reporting cervical cytology exist which allow some cervical screening 
data compiled and reported by the AIHW to be compared with data that are also sourced 
from state and territory cervical screening registers for a different purpose. 
Coherence 
Cervical screening data are reported and published annually by the AIHW. Changes in 
reporting practices over time are clearly noted throughout the reports. 
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Appendix E: Classifications 
Age 
The data in this report are stratified by the age of the woman at the time of the specified test 
(for screening data), at the time of diagnosis (for cancer incidence data) or at the time of 
death (for cancer mortality data). 
State or territory 
The state or territory reported is the one where screening took place (for the screening data), 
where the diagnosis was made (for the cancer incidence data) or the place of usual residence 
(for the cancer mortality data). 
This means that it is possible for a woman to be double-counted in the screening data. If she 
was screened in one jurisdiction and then screened again less than 2 years later in another 
jurisdiction, both screens may be included in participation. This should, however, have a 
negligible effect on the reported participation. 
Remoteness area 
The remoteness areas (RAs) divide Australia into broad geographic regions that share 
common characteristics of remoteness for statistical purposes. The remoteness structure 
divides each state and territory into several regions on the basis of their relative access to 
services. There are 6 classes of RA in the remoteness structure: Major cities, Inner regional, 
Outer regional, Remote Australia, Very remote and Migratory. The category Major cities includes 
Australia’s capital cities, except for Hobart and Darwin, which are classified as Inner regional. 
RAs are based on the Accessibility and Remoteness Index of Australia produced by the 
Australian Population and Migration Research Centre at the University of Adelaide. 
Remoteness area for participation calculations 
For participation calculations, women were allocated to a remoteness area using their 
residential postcode supplied at the time of screening. Caution is required when examining 
differences across remoteness areas. First, postcodes used to allocate women may not 
represent their location of residence. Second, because these are based on the 2011 census, the 
accuracy of remoteness area classifications diminishes due to subsequent changes in 
demographics. Third, some postcodes (and hence some individual women) are unable to be 
allocated to a remoteness area.  
Remoteness area for incidence and mortality calculations 
Each unit record in the ACD contains the 2006 Statistical Local Area (SLA) and 2011 
Statistical Area Level 2 (SA2) but not the remoteness area. In order to calculate the cancer 
incidence rates by remoteness area, a correspondence was used to map the 2006 SLA to the 
2006 RA. Similarly, the cancer mortality rates by remoteness area were calculated by 
applying a correspondence from the 2011 SA2 to the 2011 RA. 
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Socioeconomic status 
The Index of Relative Socio-economic Disadvantage (IRSD) is one of four Socio-Economic 
Indexes for Areas (SEIFAs) developed by the ABS. This index is based on factors such as 
average household income, education levels and unemployment rates. The IRSD is not a 
person-based measure; rather, it is an area-based measure of socioeconomic disadvantage in 
which small areas of Australia are classified on a continuum from disadvantaged to affluent. 
This information is used as a proxy for the socioeconomic disadvantage of people living in 
those areas and may not be correct for each person in that area. 
In this report, the first socioeconomic status group (quintile 1) corresponds to geographical 
areas containing the 20% of the population with the greatest socioeconomic disadvantage 
according to the IRSD (that is, the lowest socioeconomic group), and the fifth group 
(quintile 5) corresponds to the 20% of the population with the least socioeconomic 
disadvantage (that is, the highest socioeconomic group). 
Socioeconomic status for participation calculations  
For participation, women were allocated to a socioeconomic status using their residential 
postcode supplied at the time of screening. Caution is required when examining differences 
across socioeconomic status for several reasons. First, postcodes used to allocate women may 
not represent their location of residence. Second, because these are based on the 2011 census, 
the accuracy of socioeconomic status classifications diminishes due to subsequent changes in 
demographics. Third, many postcodes (and hence women) are unable to be allocated to a 
socioeconomic status group. 
Socioeconomics status for incidence and mortality calculations 
Socioeconomic status quintiles were assigned to cancer cases according to the IRSD of the 
SLA of residence at the time of diagnosis, and to deaths according to the Statistical Area 
Level 2 (SA2) of residence at the time of death. 
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Appendix F: Statistical methods 
Comparisons and tests of statistical significance 
This report includes statistical tests of the significance of comparisons of rates between 
population groups. Any statistical comparison applied to one variable must take account of 
any other potentially relevant variables. For example, any comparison of participation by 
state must also take account of differences in the distribution of age and sex between the 
states. These other variables are known as ‘confounding’ variables. 
Crude rates 
A ‘crude rate’ is defined as the number of events over a specified period of time (for 
example, a year) divided by the total population. For example, a crude cancer incidence rate 
is similarly defined as the number of new cases of cancer in a specified period of time 
divided by the population at risk. Crude mortality rates and cancer incidence rates are 
expressed in this report as number of deaths or new cases per 100,000 population. Crude 
participation rate is expressed as a percentage. 
Age-specific rates 
Age-specific rates provide information on the incidence of a particular event in an age group 
relative to the total number of people at risk of that event in the same age group. It is 
calculated by dividing the number of events occurring in each specified age group by the 
corresponding ‘at-risk’ population in the same age group and then multiplying the result by 
a constant (for example, 100,000) to derive the rate. Age-specific rates are often expressed per 
100,000 population. 
Age-standardised rates 
A crude rate provides information on the number of, for example, new cases of cancer or 
deaths from cancer in the population at risk in a specified period. No age adjustments are 
made when calculating a crude rate. Since the risk of cancer is heavily dependent on age, 
crude rates are not suitable for looking at trends or making comparisons across groups in 
cancer incidence and mortality. 
More meaningful comparisons can be made by the use of age-standardised rates (ASRs), 
with such rates adjusted for age in order to facilitate comparisons between populations that 
have different age structures—for example, between Indigenous people and other 
Australians. This standardisation process effectively removes the influence of age structure 
on the summary rate. 
There are 2 methods commonly used to adjust for age: direct and indirect standardisation. In 
this report, the direct standardisation approach presented by Jensen and colleagues (1991) is 
used. To age-standardise using the direct method, the first step is to obtain population 
numbers and numbers of cases (or deaths) in age ranges, typically 5-year age ranges. The 
next step is to multiply the age-specific population numbers for the standard population (in 
this case, the Australian population as at 30 June 2001) by the age-specific incidence rates (or 
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death rates) for the population of interest (such as those in a certain socioeconomic status 
group or those who lived in Major cities). The next step is to sum across the age groups and 
divide this sum by the total of the standard population to give an ASR for the population of 
interest. Finally, this is expressed per 1,000 or 100,000 as appropriate. 
Confidence intervals 
Population numbers for incidence and mortality and screening have a natural level of 
variability for a single year above and below what might be expected in the mean over many 
years. The percentage variability is small for large population numbers but high for small 
numbers such as mortality in a young age group. One measure of the likely difference is that 
of standard error, which indicates the extent to which a population number might have 
varied by chance in only 1 year of data. In the 95% confidence interval, there are about 19 
chances in 20 that the difference will be less than 2 standard errors. 
There are several methods for calculating confidence intervals. The 95% confidence intervals 
(CIs) in this report were calculated using a method developed by Dobson and others (1991). 
This method calculates approximate confidence intervals for a weighted sum of Poisson 
parameters. 
Interpretation of confidence intervals 
Some indicators have a 95% confidence interval presented along with the rates. This is 
because the observed value of a rate may vary due to chance, even where there is no 
variation in the underlying value of the rate. The 95% confidence interval represents a range 
(interval) over which variation in the observed rate is consistent with this chance variation. 
In other words, there is a 95% confidence that the true value of the rate is somewhere within 
this range. 
These confidence intervals can be used as a guide to whether differences in a particular rate 
are consistent with chance variation. Where the confidence intervals do not overlap, the 
difference between rates is greater than that which could be explained by chance, and is 
regarded as statistically significant. 
It is important to note that the overlapping of confidence intervals does not imply that the 
difference between 2 rates is definitely due to chance. Instead, an overlapping confidence 
interval represents a difference in rates that is too small to allow differentiation between a 
real difference and one that is due to chance variation. It can therefore only be stated that no 
statistically significant differences were found, and not that no differences exist. 
The approximate comparisons presented might understate the statistical significance of some 
differences, but they are sufficiently accurate for the purposes of this report. 
As with all statistical comparisons, care should be exercised in interpreting the results of the 
comparison. If 2 rates are statistically significantly different from each other, this means that 
the difference is unlikely to have arisen by chance. Judgment should, however, be exercised 
in deciding whether or not the difference is of any clinical significance. 
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Glossary 
Aboriginal: A person of Aboriginal descent who identifies as an Aboriginal and is accepted 
as such by the community in which he or she lives. 
cytology: Cytology means ‘study of cells’ and, in the context of cervical screening, refers to 
cells from the cervix that are collected and examined for abnormalities. Cervical cytology 
using the Pap test is the primary screening tool of the NCSP. 
endocervical abnormality (cytology): An endocervical abnormality is defined as an 
endocervical result of ‘E2 Atypical endocervical cells of uncertain significance’, ‘E3 Possible 
high-grade endocervical glandular lesion’, ‘E4 Adenocarcinoma in situ’, ‘E5 Adenocarcinoma 
in situ with possible microinvasion/invasion’ or ‘E6 Adenocarcinoma’, regardless of the 
corresponding squamous result for that cytology test. 
endocervical abnormality (histology): An endocervical abnormality is defined as an 
endocervical result of ‘HE02 Endocervical atypia’, ‘HE03.1 Endocervical dysplasia’, ‘HE03.2 
Adenocarcinoma in situ’, ‘HE04.1 Microinvasive adenocarcinoma’, ‘HE04.2 Invasive 
adenocarcinoma’, ‘HE04.3 Adenosquamous carcinoma’ or ‘HE04.4 Carcinoma of the cervix 
(other)’ regardless of any squamous result. Note that HE04.3 Adenosquamous carcinoma 
and HE04.4 Carcinoma of the cervix (other) are included as endocervical abnormalities for 
data reporting purposes, but that the former is not solely of endocervical origin, and the 
latter category comprises rarer carcinomas of other epithelial origin. 
high-grade abnormality detection rate: The number of women per 1,000 screened with a 
histologically-confirmed high-grade abnormality (cervical intraepithelial neoplasia (CIN) 
that has been graded as ‘moderate’ (CIN II) or ‘severe’ (CIN III), or for which the grade has 
not been specified; endocervical dysplasia; or adenocarcinomain situ). 
high-risk HPV: High-risk HPV types are those that are associated with the development of 
cervical cancer. Currently 15 high-risk types of HPV are recognised. HPV types 16, 18, and 45 
are most predominantly associated with cervical cancer, with HPV types 16 and 18 detected 
in 70–80% of cases of cervical cancer in Australia (Brotherton 2008). 
histology: Histology is the examination of tissue from the cervix through a microscope, and 
is the primary diagnostic tool of the NCSP. 
HPV: Human papillomavirus, a virus that affects both males and females. There are around 
100 types of HPV, with around 40 types known as genital HPV that are contracted through 
sexual contact. Persistent infection with high-risk HPV types can lead to cervical cancer, 
whereas infection with low-risk types of HPV can cause genital warts.  
negative cytology: Negative cytology is defined as a cervical cytology test where the 
squamous result is ‘S1 Negative’ and the endocervical result is either ‘E0 No endocervical 
component’ or ‘E1 Negative’. 
no endocervical component: A cytology test with no endocervical component is defined as a 
cervical cytology test with any squamous result and an endocervical result of ‘E0 No 
endocervical component’, meaning that no endocervical cells are present in the sample, and 
thus only the squamous cells in the sample can be assessed for the presence of abnormalities 
or cancer. 
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Pap test: Papanicolaou smear, a procedure to detect cancer and pre-cancerous conditions of 
the female genital tract, which is the screening test of the National Cervical Screening 
Program. During a Pap test, cells are collected from the transformation zone of the cervix—
the area of the cervix where the squamous cells from the outer opening of the cervix and 
glandular cells from the endocervical canal meet. This is the site where most cervical 
abnormalities and cancers are detected. For conventional cytology, these cells are transferred 
onto a slide, and sent to a pathology laboratory for assessment. Collected cells are then 
examined under a microscope to look for abnormalities. 
National HPV Vaccination Program: The National HPV Vaccination Program was first 
introduced on 1 April 2007 as a program for females.At its inception it comprised an ongoing 
program for females aged 12–13 administered through schools, as well as a catch-up 
program for females aged 13–26 between 2007 and 2009, with females aged 13–17 vaccinated 
through schools and females aged 18–26 vaccinated through the community. From February 
2013, the current school-based program for females aged 12–13 was extended to males aged 
12–13, with a catch-up program in 2013 and 2014 for males aged 14–15. 
screening: Screening refers to the application of a test to a population which has no overt 
signs or symptoms of the disease in question, to detect disease at a stage when treatment is 
more effective. The screening test is used to identify people who require further investigation 
to determine the presence or absence of disease and is not primarily a diagnostic test. 
The purpose of screening an asymptomatic individual is to detect early evidence of an 
abnormality or abnormalities, such as pre-malignant changes (for example, by Pap test) or 
early invasive malignancy (for example, by mammography), in order to recommend 
preventive strategies or treatment that will provide a better health outcome than if the 
disease were diagnosed at a later stage. 
It is a commonly held belief among health professionals and the community that ‘early 
diagnosis’ of cancer is beneficial and therefore screening is bound to be effective. However, it 
cannot be assumed that each person who has a screen-detected abnormality or cancer within 
a screening program will benefit from that diagnosis. For example, it is now understood that 
a substantial proportion of early abnormalities on Pap tests (that is, dysplastic changes) will 
regress without treatment. The potential benefits of organised population screening program 
for cancer must thus outweigh any potential harms that may result in the use of a screening 
test in people who are otherwise well. 
squamous abnormality (cytology): A squamous abnormality is defined as a squamous result 
of ‘S2 Possible low-grade squamous intraepithelial lesion’, ‘S3 Low-grade squamous 
intraepithelial lesion’, ‘S4 Possible high-grade squamous intraepithelial lesion’, ‘S5 High-
grade squamous intraepithelial lesion’, ‘S6 High-grade intraepithelial lesion with possible 
microinvasion/invasion’ or ‘S7 Squamous cell carcinoma’, regardless of the corresponding 
endocervical result for that cytology test. 
squamous abnormality (histology): A squamous abnormality is defined as a squamous 
result of HS02 Low-grade squamous abnormality, HS03.1 Cervical intraepithelial neoplasia 
(CIN) not otherwise specified (NOS), HS03.2 CIN II, HS03.3 CIN III, HS04.1 Microinvasive 
squamous cell carcinoma, or HS04.2 Invasive squamous cell carcinoma, regardless of any 
endocervical result. 
unsatisfactory cytology: Unsatisfactory cytology is defined as a cervical cytology test where 
the squamous result is ‘SU Unsatisfactory’ and the endocervical result is ‘EU Unsatisfactory’ 
or where the squamous result is ‘SU Unsatisfactory’ and the endocervical result is either ‘E0 
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No endocervical component’ or ‘E1 Negative’. While not a true result per se, ‘unsatisfactory 
cytology’ means that, due to the unsatisfactory nature of the cells sampled, the pathologist is 
unable to determine a clear result. This may be due to either too few or too many cells, or the 
presence of blood or other factors obscuring the cells, or to poor staining or preservation. The 
absence of an endocervical component is not considered sufficient grounds to deem a 
cervical cytology sample unsatisfactory (NPAAC 2006). 
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